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SUMMARY 
 
Although spinal cord injury (SCI) is a debilitating condition that presents a large 
socioeconomic problem in the United States, there is currently no treatment that reliably 
reduces morbidity and mortality.  Current research is aimed at identifying mechanisms 
involved in the pathophysiology of SCI and using this knowledge to develop rational 
treatments.  We have observed plasma membrane compromise in the acute (within 10 
minutes), sub-acute (3 days),  and chronic phases (5 weeks) in a rat model of contusion 
SCI and postulate that it negatively affects neurological outcome.  Holes/tears in the 
plasma membrane were assessed with a dye exclusion assay, in which a fluorescent cell-
impermeant dye was injected into the cerebrospinal fluid prior to sacrifice; therefore, 
cellular uptake of the dye is indicative of plasma membrane compromise.  As early as 10 
minutes after SCI, widespread uptake of permeability markers was evident in neuronal 
cell bodies as well as axonal projections.  The number of permeable cells and the size of 
the membrane breaches (measured by using permeability markers of various sizes) varied 
with distance from the injury site, with larger disruptions located closer to the epicenter.  
Greater cellular uptake was observed when the impact force was increased (200 > 150 > 
100 kdyn > sham).  At longer time points (3 days and 5 weeks), substantial permeability 
marker uptake was observed in axons but not in cell bodies. Cells with increased 
permeability displayed a variety of pathomorphological alterations, including swelling, 
blebbing, retraction bulb formation, neurofilament loss, and fragmentation, suggesting 
that increased plasma membrane permeability is detrimental to cell survival and function.  
We therefore investigated a clinically-relevant treatment strategy designed to restore 
plasma membrane integrity.  Animals were treated with citicoline, a molecule utilized in 
 xii
the endogenous synthesis of phosphatidylcholine (the major membrane component in 
mammalian cells).  Citicoline has been shown to be beneficial in numerous studies of 
neurological disease, improving overall outcome by increasing phospholipid synthesis 
and attenuating phospholipid destruction (by reducing phospholipase A2 activity).  
However, these mechanisms have not been explored in a model of SCI.  When compared 
to injured animals receiving vehicle (saline) injections, citicoline treatment after SCI did 
not have a statistically significant effect on cytoplasmic PLA2 activity (at 24h post-
injury), the density of permeable axons (at 3 days post-injury), or the lesion volume (at 3 
days post-injury).  Since citicoline may improve neurological outcome after SCI through 
mechanisms we did not directly assess, we then conducted a longer-term study to 
evaluate the overall efficacy of citicoline treatment in terms of longer-term functional and 
histological consequences.  Citicoline did not have a biologically significant effect on 
behavioral recovery (evaluated during open field locomotion, grid walk and hyperalgesia 
testing weekly for up to 5 weeks post-injury) or lesion volume (at 5 weeks post-injury).  
The lack of citicoline-mediated effect may be attributed to experimental parameters (e.g., 
dosing or sensitivity of outcome measures) or biological inefficacy.  Although we were 
not able to demonstrate that citicoline improves outcome after SCI, the finding that 
plasma membrane damage occurs in a persistent fashion and is associated with 
pathophysiological cellular alterations may provide fundamental knowledge necessary for 
developing treatments targeted at membrane repair.  Future work examining the complex 
mechanisms causing prolonged membrane damage after SCI and evaluating strategies for 
manipulating these pathways (potentially using citicoline in combination with other 
pharmacological agents) may lead to a clinically effective therapy. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
Overview of Spinal Cord Injury 
There are an estimated 12,000 new cases of spinal cord injury (SCI) each year in 
the United States (Albin and White 1987; Sekhon and Fehlings 2001).  Depending on the 
location and severity of the injury, persons with an SCI may experience neurological 
dysfunction such as paralysis, neuropathic pain, bladder and bowel dysfunction, and 
impotency.  This is particularly devastating to the patient, since most are under the age of 
30 and are otherwise healthy (Nobunaga et al. 1999).  Although physical and emotional 
states are dramatically affected in these individuals, the currently available treatments 
offer modest benefit if any at all (Baptiste and Fehlings 2007; Hall and Springer 2004; 
Sayer et al. 2006).  Thus, SCI remains a major socioeconomic problem in the United 
States, with lifetime costs ranging from $500,000 to more than $2 million per patient in 
addition to a loss of income (Sekhon and Fehlings 2001).  
The pathophysiology of SCI begins with a mechanical insult that surpasses 
structural thresholds to inflict damage on tissue and cellular levels.  Trauma is most 
commonly inflicted by vehicle accidents, but also occurs as a result of falls, violence, or 
sports-related injuries (Nobunaga et al. 1999).  Typically the injury is incomplete, 
meaning that the spinal cord is damaged but not completely transected.  Hemorrhage, 
necrosis, and cell rupture occur immediately at the injury site in an irreparable fashion.  
These early events (collectively termed primary injury) set into motion a complex series 
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of events that result in prolonged cell death and axonal degeneration (secondary injury).  
Factors contributing to secondary injury include ischemia, blood-spinal cord barrier 
breakdown, formation of the glial scar, and neuroinflammation among many other 
pathophysiological phenomena.  As a result of these secondary injury mechanisms, the 
lesion expands over the following days, weeks, and even months to create a fluid-filled 
cystic cavity within the spinal cord parenchyma (for review, see (Dumont et al. 2001; 
Hagg and Oudega 2006; Kwon et al. 2004)). 
Since a large portion of the cell death inflicted by SCI accumulates over time due 
to secondary injury mechanisms, it is feasible that a treatment given after the injury can 
reduce the total amount of tissue damage.  Methylprednisolone, the current standard of 
care for persons with SCI, is a neuroprotective agent shown to attenuate tissue damage 
and promote functional recovery in animal models by attenuating lipid peroxidation 
(Braughler and Hall 1982; Constantini and Young 1994; Hall 1992).  However, use of 
methylprednisolone in humans remains controversial because of the risk of harmful side 
effects (e.g, septic shock, pneumonia, gastrointestinal bleeding, and wound infection) in 
the face of only minor functional improvements (Fehlings 2001; Hall and Springer 2004; 
Hurlbert 2000; Sayer et al. 2006).  Therefore, the development of a safe and effective 
treatment for SCI remains a priority for researchers and clinicians.  Accordingly, the goal 
of this thesis project was to identify and characterize a pathophysiological mechanism of 
SCI, and then test a clinically relevant treatment strategy that targets this source of 
damage. 
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Plasma membrane damage as a therapeutic target for SCI treatment 
 
Plasma membrane damage after CNS injury 
 
 The plasma membrane serves as a barrier that maintains the structure and 
organization of cell, regulates molecular transport, and sustains concentration gradients 
essential for cell survival and function.  Plasma membrane disruptions have been 
observed in many models of traumatic CNS injury (Choo et al. 2007; Geddes-Klein et al. 
2006; Geddes et al. 2003; LaPlaca et al. 1997; Pettus et al. 1994; Prado et al. 2005; Shi 
2004; Shi et al. 2000; Whalen et al. 2007).  Non-specific pores in the plasma membrane 
occur in the initial phase of traumatic CNS injury (within minutes) as a direct result of 
mechanical forces that have surpassed the structural threshold of the cell.  This is not 
entirely surprising, considering the plasma membrane of other cell types are known to 
rupture as a result of a mechanical perturbation (Clarke et al. 1995; Guzman et al. 2001; 
McNeil 1989; Schlicher et al. 2006; Yu and McNeil 1992).  However, this phenomenon 
has largely been unexplored in models of CNS trauma and many questions remain 
unanswered in regard to the fate of permeabilized cells. 
Plasma membrane disruptions likely play a large role in the pathophysiology of 
SCI, especially given the importance of the lipid bilayer in maintaining homeostasis and 
the finding that permeability changes have been shown to persist for days to weeks after 
traumatic CNS injury (Farkas et al. 2006; Shi 2004; Whalen et al. 2007).  It is currently 
unknown whether long-term membrane damage is caused by: 1) an inability to reseal 
mechanically-induced holes in the plasma membrane, 2) the presence of a persistent 
stimulus in the post-injury environment that generates new membrane breaches (e.g., free 
radicals or phospholipase activity), or 3) a combination of the two.  Previous work 
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suggests that a combination of these mechanisms is responsible (Farkas et al. 2006; 
Whalen et al. 2007); therefore, the working hypothesis is that a subset of plasma 
membrane breaches are formed through mechanical destruction in the acute phase 
whereas others are created through secondary injury mechanisms (as depicted in Figure 
1.1). 
 The mechanisms involved in plasma membrane resealing after traumatic CNS 
injury have been explored in previous studies. Membrane repair requires calcium (Ca2+) 
entry into the cytoplasm (presumably via diffusion through the hole created in the 
membrane).  Ca2+ influx triggers vesicles to fuse with each other and also with the 
adjacent plasma membrane, thus transporting membrane components to the outermost 
cell membrane (Eddleman et al. 1997; McNeil and Terasaki 2001).  In addition, Ca2+ 
influx activates the cysteine protease calpain (Howard et al. 1999; Shi et al. 2000; Xie 
and Barrett 1991; Yawo and Kuno 1985; Yoo et al. 2003).  When combining this 
evidence with studies conducted in other cell types and injury models, it is postulated that 
calpain-mediated degradation of the actin cytoskeleton is necessary for removing the 
barrier between vesicles and the plasma membrane, thus clearing the path for vesicle-
mediated resealing (Eitzen 2003; McNeil and Kirchhausen 2005; Miyake et al. 2001).   
 Although these studies have provided valuable information about plasma 
membrane resealing after traumatic injury, it should be noted that they were conducted in 
vitro and thus are somewhat limited in their interpretation.  The in vivo scenario is more 
complex and presents different environmental conditions that may affect plasma 
membrane damage and the subsequent repair response.  Notably, the resealing time 
course is much shorter in vitro (Farkas et al. 2006; Geddes et al. 2003; Prado et al. 2005; 
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Shi 2004; Shi et al. 2000; Whalen et al. 2007), suggesting that factors found in vivo 
differentially affect membrane resealing in comparison to those represented in vitro.   For 
example, one important variable not modeled in vitro is that extracellular Ca2+ 
concentrations are dynamic and greatly depressed after SCI (Stokes et al. 1983; Young et 
al. 1982), which would presumably slow down or prevent the Ca2+-mediated membrane 
repair processes. In addition, in vitro CNS trauma models do not typically represent 
ischemia and the inflammatory response, both of which may cause plasma membrane 
damage and affect the cell’s ability to reseal.  Thus, the mechanisms contributing to 
plasma membrane compromise and repair in vivo are complex and are not completely 
understood. 
 Alterations in phospholipid metabolism following SCI may introduce additional 
factors that can exacerbate membrane permeability or delay/prevent membrane repair in 
vivo.  In general, SCI causes a shift that enhances membrane breakdown and decreases 
membrane synthesis.  Previous work has shown that SCI causes a reduction in 
phospholipid levels and an accumulation of free fatty acids (Demediuk et al. 1989a; 
Lemke et al. 1990; Murphy et al. 1994).  Phospholipids are destroyed mainly through two 
mechanisms: hydrolysis and peroxidation.  Phospholipid hydrolysis occurs through 
activation of the phospholipase A2 (PLA2) family of enzymes (Farooqui et al. 1997; Liu 
et al. 2006; Olivas and Noble-Haeusslein 2006), whereas lipid peroxidation is due to 
oxidative stress caused by an accumulation of free radicals (Anderson and Hall 1993; 
Carlson et al. 1998; Hall and Braughler 1986). 
 The interplay between these mechanisms is complex and lead to a vicious positive 
feedback cycle that destroys membrane integrity (see Figure 1.1).  PLA2 activation 
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occurs as a result of Ca2+ influx, which can be generated by ion diffusion through 
membrane disruptions (Bauldry et al. 1996).  Activated PLA2 then hydrolyzes 
phospholipids to release fatty acids.  This removal of phospholipids can compromise 
membrane integrity and lead to further Ca2+ increase, thereby activating more PLA2 
(O'Regan et al. 1996).  Moreover, the PLA2-mediated generation of fatty acids 
(arachidonic acid in particular (Demediuk et al. 1985)) leads to eicosonoid synthesis and 
generation of free radicals (Farooqui et al. 1997; Liu et al. 2006; Olivas and Noble-
Haeusslein 2006). Free radical accumulation, generated through arachidonic acid 
metabolism as well as the inflammatory response, can cause lipid peroxidation.  To 
further intensify the problem, the chemical reaction between a lipid and a free radical 
creates a lipid peroxide radical, which can subsequently react with other phospholipids in 
the membrane to produce more lipid peroxide radicals (for review see (Anderson and 
Hall 1993; Hall and Braughler 1986; McCall et al. 1987).  Thus, under 
pathophysiological conditions, the interplay between these mechanisms causes a chain 
reaction that compromises the integrity of the plasma membrane (Kumar et al. 2003). 
 In summary, plasma membrane compromise occurs after SCI and is a dynamic, 
complex pathophysiological process.  Plasma membrane damage is a result of both the 
primary insult (which causes mechanical disruption) and subsequent activation of 
secondary injury mechanisms (e.g., inflammation and enzymatic activation), as shown in 
Figure 1.1.  Traumatic CNS injury causes membrane defects that are quite large 
(allowing entry of molecules as large as 44 kDa (Pettus et al. 1994; Pettus and Povlishock 
1996; Shi et al. 2000; Shi and Whitebone 2006)), which may lead to cell death, 
degeneration, and/or dysfunction. 
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Targeting membrane repair for treatment of SCI 
Although persistent plasma membrane damage is likely to negatively influence 
post-SCI outcome, it also presents a therapeutic opportunity to restore function and 
prevent cell death/dysfunction.  Plasma membrane compromise is postulated to initiate 
numerous detrimental cellular responses by preventing the cell from maintaining 
homeostasis.  Therefore, targeting membrane repair may be an effective approach 
because it can alleviate numerous deleterious pathways at once.  Compromise of the 
plasma membrane can directly lead to cell death if the defect is large enough, but some 
cells are able to reseal or remain permeable without dying (Farkas et al. 2006; Geddes-
Klein et al. 2006; Geddes et al. 2003; Prado et al. 2005; Whalen et al. 2007).  However, it 
is likely that permeabilized cells that are able to reseal or survive without resealing can 
experience longer-term cell death and/or dysfunction through the activation of aberrant 
signaling pathways.  For example, compromise of the plasma membrane results in Ca2+ 
flux down its concentration gradient into the cell.  Ca2+ influx after CNS injury has been 
correlated with many damaging downstream events, including endonuclease activation, 
cytoskeletal breakdown, mitochondrial damage, and apoptotic cell death (for review, see 
(Dumont et al. 2001)).  In fact, increases in plasma membrane permeability have been 
associated with pathophysiological events such as protease activation (Farkas et al. 
2006), conduction block (Shi and Borgens 2000), and delayed cell death (Whalen et al. 
2007).   
 Previous research has shown that membrane resealing agents are able to provide 
benefit following CNS trauma.  It has been demonstrated the polyethylene glycol (PEG) 
mediates resealing and promote functional recovery following SCI (Borgens 2001; 
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Borgens and Shi 2000; Laverty et al. 2004; Luo et al. 2002; Luo and Shi 2007; Shi and 
Borgens 2000).  PEG is a hydrophilic polymer that promotes fusion of opposing 
membranes, thereby enhancing vesicle fusion and joining adjacent cellular membranes 
(e.g., transected axons) (Krause and Bittner 1990; Lentz and Lee 1999; Lore et al. 1999).  
Although PEG has been effective in animal models, clinical translation will require 
caution.  PEG has also been used to fuse healthy cells together (Davidson and Gerald 
1976), which may lead to unintentional harmful effects. Furthermore, prolonged PEG 
application has been shown to negatively affect both healthy and injured spinal cords 
(Cole and Shi 2005).  Therefore, patient safety will require great care in ensuring that the 
appropriate treatment regimens are followed. 
 Poloxamer 188 has also been shown to promote spinal cord repair following 
traumatic injury (Borgens et al. 2004; Follis et al. 1996; Kilinc et al. 2007; Laverty et al. 
2004; Serbest et al. 2005; Serbest et al. 2006).  The amphiphilic structure (a tri-block 
copolymer consisting of a central hydrophobic chain surrounded by 2 hydropholic 
chains), allows it to insert directly into the cell membrane, thereby promoting membrane 
repair and cell survival (Baekmark et al. 1997; Marks et al. 2001; Maskarinec et al. 2002; 
Serbest et al. 2006; Sharma et al. 1996).  These findings provide supporting evidence that 
plasma membrane damage is detrimental to post-injury outcome and that targeting 
membrane repair is an effective approach for SCI treatment.  However, a treatment that 
augments endogenous membrane repair may be safer and more clinically effective for the 
treatment of SCI. 
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Citicoline as a membrane resealing agent and therapy for SCI 
 
 Citicoline (a pharmaceutical agent identical to the endogenous molecule CDP-
choline or cytidine diphosphate choline) is a nucleotide that serves as the endogenous 
choline donor in the synthesis of acetylcholine and phospholipids (mainly 
phosphatidylcholine (PC), the major membrane component in mammalian cells) 
(Kennedy and Weiss 1956).  Citicoline cannot be made by the body and is therefore 
ingested through the diet (Best and Huntsman 1932) or found in cell culture medium 
(Vance and Vance 2004).  When ingested, citicoline is absorbed in the digestive tract 
then broken down into its components, cytidine and choline, in the gut wall and liver.  
Cytidine and choline then circulate throughout the blood stream and are utilized in 
various parts of the body for phospholipid synthesis (for review see ((Conant and Schauss 
2004; Weiss 1995)).  Choline enters cells through transporter proteins (Yamamura and 
Snyder 1972) and is then utilized for PC synthesis through several enzymatic reactions, 
as summarized in Figure 1.2 (for review see (Vance and Vance 2004)).  First, choline is 
converted to phosphocholine by the enzyme choline kinase.  Phosphocholine is then 
converted to CDP-choline by CTP:phosphocholine cytidylyltransferase. Finally, 
cholinephosphotransferase transfers phosphocholine to diacylglycerol from citicoline to 
create PC.  The importance of this mechanism in maintaining cellular function is 
underscored by experimental evidence demonstrating that blocking this pathway is 
sufficient to induce cell death in vitro (Cui and Houweling 2002; Cui et al. 1996).   
 Citicoline has shown promising results for treatment of various neurological 
diseases and disorders in humans and animals, where citicoline plays a role in both 
phospholipid production and membrane preservation (for review see (Adibhatla and 
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Hatcher 2002; Conant and Schauss 2004; Zweifler 2002)).  Exogenous citicoline 
enhanced PC levels as well as sphingomyelin and cardiolipin (a major lipid component of 
the inner mitochondrial membrane) in an animal model of stroke (Rao et al. 2000).  In 
addition to promoting plasma membrane synthesis after an ischemic insult, citicoline also 
prevents plasma membrane damage by reducing oxidative damage, decreasing 
arachidonic acid production (which reduces free radicals and lipid peroxidation), and 
attenuating PLA2 activity (Adibhatla and Hatcher 2003; Arrigoni et al. 1987; Fresta et al. 
1994; Rao et al. 1999).  Citicoline is currently approved for treatment of stroke in over 70 
countries worldwide and is undergoing clinical trials in the United States.  Initial US 
trials showed a beneficial effect (Clark et al. 1997), but subsequent trials were only 
moderately successful and depended on the criteria used (Clark et al. 2001; Davalos et al. 
2002).  As a treatment for SCI, citicoline may offer advantages over methylprednisolone, 
as almost no side effects have been observed (for review see (Adibhatla and Hatcher 
2002; Conant and Schauss 2004; Zweifler 2002)).   
Recent work has assessed the effects of citicoline as a treatment for SCI.  Cakir et 
al (2005) demonstrated that citicoline treatment improved hindlimb locomotion at 24 and 
48 hours post-SCI and reduced lipid peroxidation at 48 hours.  Yucel et al (2006) 
compared the effects of citicoline to methylprednisolone as well as a combination of 
citicoline and methylprednisolone.  At 24 hours post-SCI, citicoline attenuated lipid 
peroxidation, increased levels of the antioxidant glutathione, and decreased nitric oxide 
levels (indicative of a reduction in oxidative stress).  In addition, citicoline improved 
functional outcome (locomotor function and ability to balance on an inclined plane) and 
reduced the area of the lesion at 6 weeks post-injury.  These effects were equivalent to 
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methylprednisolone treatment but did not offer additional benefit when used in 
combination with methylprednisolone.  Thus, citicoline offers great promise as a 
treatment for SCI, but more extensive pre-clinical work can provide more information 
about the mechanisms involved and ensure that its benefits can be reproduced in various 
laboratories.  Reproducibility and detailed information about the mechanisms of action 
can provide more confidence when translating a treatment from the benchtop to the 
bedside and are therefore necessary aspects of pre-clinical research. 
Current research 
 
 This research project addresses the need to improve the current understanding of 
the pathophysiology of SCI and develop effective, clinically relevant, and 
mechanistically-driven treatments.  Our specific objectives were to better understand the 
characteristics of SCI-induced plasma membrane compromise and to test the therapeutic 
efficacy and membrane stabilizing properties of citicoline.  Since little is currently known 
about the extent of primary damage after contusion SCI, we first characterized acute 
plasma membrane damage as a function of injury severity and pore size (Chapter 2).  
Results showed that the vast majority of cells and axons at the injury site were damaged 
by the mechanical insult and that plasma membrane defects were associated with 
pathological changes in morphology.  Our findings show that membrane permeability is 
widespread and suggest that it can have a significant role in cell death/dysfunction 
following SCI. 
Membrane damage persisted for at least 5 weeks post-SCI (Chapter 4), which 
provided motivation for administering the membrane stabilization agent citicoline as a 
treatment.  We assessed the effects of citicoline on membrane integrity and PLA2 activity 
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(Chapter 3), since these are the primary mechanisms postulated to lead to citicoline-
mediated improvements after stroke and they have not been investigated in a model of 
SCI (Adibhatla and Hatcher 2003; Arrigoni et al. 1987).  However, citicoline treatment 
did not reduce PLA2 activity at 24 hours, nor did it attenuate plasma membrane 
compromise or lesion volume at 3 days post-SCI.   
To address the possibility that citicoline requires more than 3 days to have an 
effect, we conducted a longer-term study assessing behavioral and histological outcomes 
(Chapter 4).  Treatment with citicoline did not have a biologically significant effect on 
hindlimb function or lesion volume.  Although we were unable to reproduce the findings 
from other studies (Cakir et al. 2005; Yucel et al. 2006), it should be noted that we 
delivered citicoline at higher doses and more frequently (which was more consistent with 
the stroke literature but different from previous SCI research).  Future work assessing 
citicoline dosing and the mechanisms of chronic plasma membrane damage may lead to 
an effective membrane repair strategy for SCI treatment. 
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Figure 1.1: Mechanisms involved in SCI-induced plasma membrane damage. Plasma 
membrane compromise is caused by both primary and secondary injury pathways, 
ultimately affecting cell survival and function.  The mechanical insult can disrupt the 
membrane in the acute phase by surpassing structural thresholds.  Sustained membrane 
damage can occur through phospholipid hydrolysis or lipid peroxidation.  Phospholipids 
are hydrolyzed by PLA2, which results in the production of arachidonic acid, a mediator 
of free radical formation. Free radicals destroy the membrane through lipid peroxidation, 
which generates additional free radicals in a positive-feedback cycle.   
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Figure 1.2: Schematic of endogenous phosphatidylcholine synthesis.  Citicoline plays 
a fundamental role in the maintenance and preservation of the plasma membrane.  
Citicoline enters the digestive tract and is broken down into its components cytidine and 
choline in the gut and liver (not shown in this diagram).  Choline enters the tissue and is 
transported intracellularly, where it is utilized for the synthesis of phosphatidylcholine 
according to the pathway illustrated here. 
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CHAPTER 2 
ACUTE PLASMA MEMBRANE COMPROMISE CAUSED BY 
SPINAL CORD CONTUSION INJURY 
 
Introduction 
 
 Spinal cord injury (SCI) is a debilitating condition that dramatically affects 
quality of life for the affected individual and their families.  Clinically available 
treatments provide modest benefit, if any at all; therefore ongoing research is aimed at 
developing more effective therapies for spinal cord repair and regeneration (for review 
see (Baptiste and Fehlings 2007; Hall and Springer 2004; Kwon et al. 2004)).  A greater 
understanding of the time course of destructive and degenerative mechanisms involved in 
SCI is expected to improve the ability to develop targeted therapeutic strategies. 
In the acute phase of SCI, primary damage occurs as a direct result of trauma 
when structural thresholds are surpassed, leading to immediate physical and biochemical 
cellular alterations.  As a result of these immediate changes, a complex secondary injury 
cascade is initiated and ensues in the following hours, weeks, and months.  Secondary 
injury mechanisms such as apoptotic cell death, inflammation, and formation of the glial 
scar are considered to be largely deleterious to regeneration and are commonly targeted 
for treatment of SCI (Dumont et al. 2001; Hagg and Oudega 2006).  Although it is well-
documented that increasing the severity of loading parameters exacerbates tissue damage 
and neurological dysfunction (Basso et al. 1996a; Beattie et al. 1997; Kloos et al. 2005; 
Scheff et al. 2003; Wrathall et al. 1985), relatively little is known about how the 
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mechanical impact (primary injury) initiates secondary injury.  Improving the current 
understanding of the characteristics of primary damage after contusion SCI can facilitate 
a better understanding of acute injury mechanisms and their relationship to the overall 
pathophysiology. 
 One direct result of the mechanical impact in traumatic CNS injury is the 
formation of non-specific breaches in the neuronal plasma membrane.  Plasma membrane 
compromise has been observed in many models of neuronal injury and is postulated to be 
detrimental to post-injury outcomes (Farkas and Povlishock 2007; LaPlaca et al. 1997; 
LaPlaca et al. 2007; Pettus et al. 1994; Pettus and Povlishock 1996; Povlishock and 
Pettus 1996; Shi 2004; Shi et al. 2000; Singleton and Povlishock 2004; Stone et al. 2004; 
Whalen et al. 2007).  Under physiologic conditions, the plasma membrane serves as a 
barrier that maintains the structure and organization of the cell, regulates molecular 
transport, and preserves concentration gradients essential for cell survival and function.  
However, these homeostatic mechanisms are disrupted when mechanical impact to CNS 
tissue physically ruptures the plasma membrane.  Although many permeabilized cells die 
immediately through necrosis, a subset are able to reseal without undergoing acute cell 
death or degeneration (Farkas et al. 2006; Shi 2004; Shi et al. 2000; Whalen et al. 2007).  
Surviving cells, however, may experience downstream consequences of plasma 
membrane compromise (for review see (Barbee 2005; Farkas and Povlishock 2007)).  By 
temporarily or permanently destroying the barrier between the cytosol and the 
extracellular fluid, ions and other molecules could freely enter or exit the cell.  This 
unregulated molecular flux would be expected to negatively affect cell function and 
survival.  For example, Ca2+ influx down its concentration gradient would result in 
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mitochondrial damage, aberrant enzyme activation, and apoptotic cell death (for review 
see (Dumont et al. 2001)).  In fact, increases in plasma membrane permeability after CNS 
injury have been associated with pathophysioglogical events such as protease activation 
(Farkas et al. 2006), conduction block (Shi and Borgens 2000), and delayed cell death 
(Whalen et al. 2007).  Although membrane compromise may play a critical role in the 
pathophysiology of SCI, little is known about the anatomical distribution of permeable 
cells within the injured spinal cord or the size of the membrane defects in those cells. 
 The objective of this study was to better characterize acute plasma membrane 
damage induced by in vivo contusion SCI, since membrane compromise may be an 
initiating factor for numerous deleterious events.  The spatial profile of cellular damage 
was assessed as a function of injury severity and the size of the plasma membrane defect 
in a rat contusion model.  Results obtained in this study aid in defining the extent of SCI-
induced primary damage and can facilitate the discovery of pathophysiological 
mechanisms involved in transducing a mechanical input into a cellular response. 
Methods 
Surgical procedures 
All procedures involving animals were approved by the Georgia Tech 
Institutional Animal Care and Use Committee (protocol A05003).  Male Sprague-Dawley 
rats (275-400g; total n = 35) were anesthetized with sodium pentobarbital (Nembutal, 50 
mg/kg).  Isoflurane (1-3%) was used to maintain anesthesia when necessary. Animals 
were placed on a stereotaxic apparatus and the atlantoocipital membrane was surgically 
exposed.  An incision was made in the dura, and a catheter composed of PE10 tubing was 
attached to the needle of a Hamilton syringe and inserted into the intrathecal space.  A 
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fluorescent dye normally unable to penetrate the cell membrane was injected slowly over 
10 minutes (4% lucifer yellow in deionized water, 2.5% FITC-conjugated 10kDa dextran 
(10dex) in saline, or 2.5% FITC-conjugated 3kDa dextran (3dex) in saline; 15-20 µl total 
volume).  All permeability markers were obtained from Invitrogen (Carlsbad, CA).  A 
summary of the molecular weight and corresponding radius can be found in Table 2.1.  
Concentrations and solvents were based on previous studies assessing plasma membrane 
damage in neural tissue (Choo et al. 2007; Farkas et al. 2006; Howard et al. 1999).  Ten 
minutes after the dye injection, the catheter was removed and the muscle and skin at the 
surgical site was sutured closed. 
 Permeability dyes were allowed to diffuse throughout the CSF for 3h prior to 
injury.  SCI was induced according to methods described in detail elsewhere in this thesis 
(Appendix A).  Briefly, a laminectomy was performed at T10 vertebral level to expose 
the underlying spinal cord tissue.  Three injury severities were used to examine the 
distribution of membrane damage: 100, 150, or 200 kdyn impact force (Infinite Horizons 
device; Precision Systems and Instrumentation, Lexington, KY).  These forces 
correspond to mild, moderate, and severe injury levels, respectively according to 
histological and behavioral outcome measures (Scheff et al. 2003).  Sham animals were 
subjected to all surgical procedures including the dye injection and laminectomy, but the 
spinal cord was not impacted.  Animals were transcardially perfused 10 minutes 
following SCI with phosphate buffered saline (PBS) followed by fixative (4% 
paraformaldehyde / 0.1% gluteraldehyde in PBS).  The vertebral column was 
subsequently removed from the rat and immersed in fixative at 4ºC.  After 24h, spinal 
cord tissue was dissected from the vertebral column and placed in sucrose at 4ºC.  Tissue 
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was cut into 2cm segments, frozen in OCT, and then cryosectioned in the transverse 
plane. 
Verification of cellular uptake of permeability markers  
Immunohistochemistry was performed using thin sections (10 µm) to verify that 
permeability marker uptake was neuronal.  Primary antibodies specific for neurofilament-
160 (NF-160, 1:100; Sigma NF264, St. Louis, MO), NeuN (1:100; Millipore MAB377, 
Billerica, MA), and glial fibrillary acidic protein (GFAP, 1:500; Millipore MAB360) 
were used to identify axonal projections, neuronal cell bodies, and astrocytes in the 
tissue, respectively.  Briefly, slides were rinsed in PBS then immersed in 
blocking/permeabilization solution (8% goat serum and 0.4% Triton X100 in PBS) for 1 
hour at room temperature.  Sections were then incubated in primary antibody solution 
(primary antibody diluted in 8% goat serum and 0.4% Triton X100 in PBS) overnight at 
4°C in a humidified chamber.  Slides were rinsed in PBS then incubated in AlexaFluor 
546 or 568 (1:500, Invitrogen) secondary antibody solution (2% goat serum in PBS) for 
2h at room temperature in a humidified chamber.  Following a final rinse in PBS, slides 
were coverslipped using an aqueous mounting medium.  Images were obtained at 40x 
magnification using a confocal microscope (LSM 510, Carl Zeiss MicroImaging Inc., 
Thornwood, NY). 
Quantification of permeability marker uptake in cell bodies   
Three different fluorescent dyes (lucifer yellow, 3dex, or10dex) were used to 
assess membrane damage in neuronal cell bodies.  Lucifer yellow uptake was assessed 
after sham surgery or mild, moderate, and severe injury (100, 150, or 200 kdyn impact 
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force) in order to investigate whether plasma membrane damage is dependent upon 
impact force.  Additional experiments compared uptake of 3dex and 10dex in order to 
better characterize the size of SCI-induced membrane defects. 
Uptake of permeability markers was quantified at 1mm increments up to 3mm 
from the injury epicenter in both the rostral and caudal directions (n=3-5 rats per group).  
The number of permeable cells was quantified in thick sections (35 µm) to allow for 
visualization of large motor neurons.  Cells were counted manually with the assistance of 
StereoInvestigator software (MBF Bioscience, Williston, VT).  Although the fluorescent 
dyes accumulated around blood vessels, only cells with neuronal morphology (as shown 
in Figure 2.1) were included in the quantification.  Sections at the injury epicenter were 
excluded from the analysis because the extensive tissue damage did not permit reliable 
cell counts.  In order to reduce variability, two adjacent sections were counted at each 
1mm increment distance from the epicenter, and these values were averaged together to 
yield one data point per animal at each distance.  Data were analyzed using two-way 
repeated measures ANOVA followed by Tukey’s pairwise comparisons, with distance 
from the epicenter and impact force or dextran size as the independent variables and the 
number of positive cells as the dependent variable. 
Quantification of axonal uptake of dextran molecules   
The density of dextran-positive axons was quantified within thin sections (10 µm) 
using ImageJ software (National Institutes of Health, Bethesda, Maryland).  Lucifer 
yellow was not observed within axonal projections, possibly due to dye leakage or rapid 
diffusion of the small molecule along the axon.  Montage images of each section were 
acquired at 10x magnification using NeuroLucida software (MBF Bioscience).  The 
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density of permeable axons was determined within an area of approximately 85 µm2 in 
ventral, dorsal, and lateral regions.  Within these areas, thresholds for fluorescence 
intensity (determined by a blinded observer) and size (0.25-25 µm2) were used to 
eliminate autofluorescent debris from the analysis.  Each section was quantified using 
two independent measurements in each quadrant of the section (ventral, dorsal, lateral 
left, and lateral right) and an average was taken.  Data were analyzed using two-way 
repeated measures ANOVA followed by Tukey’s pairwise comparisons, with distance 
from the epicenter and dextran size as the independent variables and the number of 
positive cells as the dependent variable. 
Assessment of cellular morphology   
Cellular morphology was evaluated in paraffin sections taken from two adult male 
Sprague-Dawley rats.  3dex was injected intrathecally 3h prior to 150kdyn spinal cord 
impact, and animals were perfused 10 min after SCI with PBS followed by 4% 
paraformaldehyde and 0.1% gluteraldehyde in PBS (as described above).  Longitudinal 
sections (5µm thick) were stained with cresyl echt violet prior to imaging.  Fluorescent 
and bright field images were obtained at 63x magnification using a confocal microscope 
(Zeiss LSM 510, Carl Zeiss Corporation, Oberkochen, Germany).  
Results 
Intra-axonal and intra-cellular uptake of fluorescent dyes following SCI 
 Immunohistochemistry confirmed that regions with intense fluorescence 
represented cellular uptake of the permeability markers.  NeuN staining demonstrated 
that dye uptake within the gray matter was neuronal (Figure 2.1, A-C).  All three 
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permeability markers (lucifer yellow, 10dex, and 3dex) were easily visualized within cell 
bodies, allowing for quantification of cells that had become permeable to the fluorescent 
dye.  Dye uptake was distributed homogenously throughout the gray matter, with no 
preferential uptake in the dorsal or ventral regions. 
 Axonal uptake of the permeability markers was verified using 
immunohistochemistry specific for NF-160.  Regions with dye accumulation co-localized 
with NF-160 staining, confirming intra-axonal uptake of the permeability marker (Figure 
2.1, D-F).   Accumulation of 10dex and 3dex was observed within axolemma.  Although 
influx of the smallest dye (lucifer yellow) was expected within axons, the presence of this 
molecule was not observed at levels above background.  The absence of intra-axonal 
lucifer yellow may be attributed to a low signal-to-noise ratio due to diffusion of the dye 
along the axon or leakage of the molecule out of large tears in the plasma membrane.  
Axonal dextran uptake was evenly dispersed at the injury epicenter, with the vast 
majority of axons taking up the dye.   
 Additionally, permeability marker uptake was observed within astrocytes (mainly 
located adjacent to blood vessels) within the spinal cord white and gray matter, as 
confirmed with immunohistochemistry specific for GFAP (data not shown).  This was 
seen in both injured and sham animals; therefore, we did not interpret this to be an SCI-
induced response.  Permeability marker uptake within cells with this morphology was not 
included in the quantification. 
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Lucifer yellow uptake within cell bodies following sham surgery or injury at mild, 
moderate, or severe impact forces 
Lucifer yellow uptake within cell bodies was quantified at 1mm increments up to 
3mm from the epicenter in the rostral and caudal directions.  Increasing the impact force 
caused a corresponding increase in the rostral-caudal extent of permeability marker 
uptake (Figure 2.2).  Interestingly, lucifer yellow uptake was asymmetrical in nature, with 
more positive cells found in the caudal direction.  Severe injury (200 kdyn) resulted in the 
greatest membrane permeability alterations, with significant differences compared to 
sham out to 2mm rostrally and 3mm caudally.  Significant lucifer yellow uptake was 
observed after mild (100 kdyn) and moderate (150 kdyn) injury in the caudal direction up 
to 1mm and 2mm, respectively.  Additionally, permeability marker uptake after impact of 
150 and 200 kdyn was significantly higher compared to mild injury at 2mm in the caudal 
direction, and 200 kdyn impact induced significantly more uptake compared to 100 kdyn 
impact at 3mm caudally.  These data demonstrate that the impact force dictates the 
anatomical distribution of plasma membrane damage. 
Plasma membrane defect size within cell bodies following SCI contusion 
We compared the cellular uptake of two different permeability markers (3dex and 
10dex) in order to characterize the size of SCI-induced defects in the plasma membrane.  
More dye uptake was observed in shams receiving lucifer yellow compared to 10dex or 
3dex, which did not allow for direct comparison of injured animals among these groups.  
Sham uptake was not significantly different for animals receiving injections of 3dex and 
10dex; therefore, these groups were combined for analysis.  Significant differences 
between sham and 3dex uptake were observed up to 2mm in the rostral and caudal 
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directions, whereas 10dex uptake was limited to 1mm in either direction (Figure 2.3).  In 
addition, 3dex uptake was greater than 10dex uptake at 1 and 2 mm caudal of the injury 
epicenter; therefore we can infer that some cells incorporating 3dex were able to exclude 
10dex in these anatomical regions.  These results show that non-specific membrane 
defects induced by contusion SCI range in size (a subset larger than 5.4 nm in diameter, a 
subset between 5.4 and 3.2 nm in diameter, and a subset excluding both molecules).  The 
size of membrane defects varied as a function of distance from the injury epicenter, with 
larger membrane defects located closer to the site of impact. 
Plasma membrane defect size in axons following SCI contusion 
Axonal uptake of 10dex and 3dex was assessed at discrete distances from the 
injury epicenter in order to determine the size of membrane defects.  Permeability marker 
uptake in shams in the 10dex and 3dex group was statistically the same at all distances; 
therefore, these animals were combined in the analysis.  Uptake of 3dex within axons 
extended 2 mm in both the rostral and caudal directions, and 10dex uptake was 
significant compared to sham up to 2 mm rostrally and 1 mm caudally.  No differences 
between 3dex and 10dex uptake were observed at any location (Figure 2.4).  From these 
results, we concluded that axonal permeability occurs following SCI and that pores are at 
least as large as 5.4 nm in diameter. 
Morphological alterations associated with plasma membrane compromise  
High magnification confocal imaging of cells within spinal cord tissue revealed 
abnormal cellular morphology in many cells taking up the permeability marker 3dex.  In 
many permeable cells, we observed pericellular blebs that were not filled with the 3dex 
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permeability marker.  Blebs were visibly less dense than the cytoplasm within the cell 
and varied in size from very large blister-like morphologies that surrounded almost the 
entire cell (typically accompanied by cellular shrinkage, Figure 2.5, D-F)  to small 
circular extensions on a small portion of the cell surface (Figure 2.5, A-C and G-I). 
Blebbing was observed in a very small subset of cells that did not take up 3dex (<1%) but 
was far more common in 3dex-positive cells.  We therefore concluded that neuronal 
blebbing is associated with plasma membrane permeability.  Although others have 
observed blebbing in response to chemical or mechanical cellular perturbation in other 
cell types (Barros et al. 2003; Keller et al. 2002; Marin-Castano et al. 2005; Mills et al. 
1998; Shi et al. 2005), we are the first to our knowledge to report neuronal blebbing in 
vivo after traumatic CNS injury. 
Discussion 
 Investigation of primary membrane permeability changes in SCI may facilitate an 
improved understanding of the overall pathophysiology and thus may lead to the 
development of treatment strategies targeted at spinal cord repair.  To this end, we 
characterized acute plasma membrane damage in a clinically relevant contusion model by 
quantifying the plasma membrane defect size in both cell bodies and axons as a function 
of insult severity and anatomical location.  Our investigation of the severity-dependence 
of membrane permeability revealed that the rostral-caudal extent of plasma membrane 
damage is related to impact force.  In this study, increasing the impact force caused a 
corresponding increase in permeability marker uptake in distal regions.  Previous studies 
have examined the relationship between injury biomechanics and plasma membrane 
permeability (Choo et al. 2007; Geddes-Klein et al. 2006; Geddes et al. 2003; Shi and 
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Whitebone 2006), but the relationship between impact force and cell membrane damage 
has not previously been investigated in an in vivo model of CNS trauma.   In vitro work 
has demonstrated that membrane permeability increases with increasing strain rate and 
magnitude in axons as well as cell bodies (Geddes et al. 2003; LaPlaca et al. 1997; Shi 
and Whitebone 2006).  In addition to a dependence upon injury parameters, the extent of 
primary damage has been shown to be a function of the mode of injury: a recent in vivo 
study demonstrated that distraction and dislocation injury results in more extensive 
plasma membrane damage in comparison to contusion SCI (Choo et al. 2007).  Our data 
provide further supporting evidence that the parameters of the mechanical impact dictate 
acute biophysical plasma membrane failure. 
We also evaluated membrane pore size by quantifying uptake of 10dex and 3dex 
molecules after moderate contusion SCI.  Examination of both permeability markers 
confirmed that spinal cord impact causes plasma membrane damage in axons and cell 
bodies.  Direct comparison of 3dex and 10dex uptake revealed differences in 
permeability marker uptake within the cell bodies located in the gray matter but not 
within axons.  Cells with larger membrane disruptions were located closer to the injury 
epicenter.  Our group has previously shown that more severe mechanical damage results 
in larger membrane defects in an in vitro model of neuronal injury (Geddes et al. 2003).  
Results obtained here further support this concept, as more severe mechanical damage is 
expected to be located near the injury epicenter (and thus corresponded to greater 
permeability marker uptake). 
Uptake of 3dex and lucifer yellow exhibited an asymmetrical pattern with a larger 
number of permeable cells in the caudal direction compared to rostral of the injury site, 
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suggesting that the caudal direction in more susceptible to primary damage.  These results 
are intriguing in light of previous studies that have shown that spinal cord tissue caudal to 
the injury experiences more gross tissue damage (Nossin-Manor et al. 2007), increased 
DNA fragmentation (Sribnick et al. 2007), and enhanced resistance to anti-apoptotic 
drugs (Ling and Liu 2007) in rats at 24 h after injury.  Taken together, the data suggests 
that events occurring within minutes of SCI (such as plasma membrane damage) may 
initiate cell death and other deleterious mechanisms manifested later in time.  One 
possible explanation for this asymmetrical cell and tissue damage is that all of these 
studies utilized a mid-thoracic contusion injury, in which the mechanical impact was 
located just rostral to the lumbar enlargement.  This may have an effect on the loading 
distribution along the spinal cord since there is proportionally more gray matter in the 
caudal direction compared to rostral, and gray matter tissue has been shown to have a 
lower threshold for mechanical failure (Ichihara et al. 2001).  In addition, this skewed 
gray-to-white matter ratio may have influenced these results because one would expect a 
larger number of cell bodies in the gray matter in the caudal direction.  Although we did 
not normalize to the total number of cells, there was no asymmetrical distribution of 
10dex or sham uptake (with any of the permeability markers we used), which would be 
expected if this effect were purely based on the total number of cells within the 
histological section. 
Quantification of axonal permeability marker uptake showed no significant 
difference between SCI-induced uptake of 10dex and 3dex; therefore, we concluded that 
axolemmal plasma membrane defects are at least 5.4 nm in diameter.  Previous studies 
have shown axonal uptake of molecules as large as 44 kDa (horseradish peroxidase) 
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(Pettus et al. 1994; Pettus and Povlishock 1996; Shi et al. 2000; Shi and Whitebone 
2006).  These data indicate that contusion injury causes larger membrane defects in axons 
compared to cell bodies.  Axons may be more vulnerable to mechanical failure because 
of their elongated morphology or anatomical location on the outer edges of the spinal 
cord.  In addition, in vitro evidence suggests that axons require much longer for resealing 
(on the order of 1 h) (Eddleman et al. 1997; Shi et al. 2000; Yoo et al. 2003), whereas 
neuronal cell bodies are able to reseal within minutes (Geddes et al. 2003; Prado et al. 
2005).  Although it is difficult to directly compare these studies due to variations in cell 
type/species, mechanical insult parameters, and the size of permeability markers, the 
results collectively suggest that cell bodies and axons differ in their structural thresholds 
and subsequent repair response.  It should also be noted that the time required for 
resealing appears to be much longer in vivo (Farkas et al. 2006; Howard et al. 1999; Shi 
2004).  Future work assessing the time course and mechanisms involved in plasma 
membrane damage in both cell bodies and axons may elucidate the reasons for this 
discrepancy and provide the foundations for developing treatment strategies aimed at 
membrane repair. 
In this study we also examined cellular morphology in permeable and non-
permeable cells at 10 min post-injury.  Blebbing was observed in cells within the injured 
spinal cord, and was almost exclusively found in the cells that took up the (3dex) 
permeability marker.  No blebs were seen in cells located distally from the injury 
epicenter, suggesting that the blebbing phenomenon is specific to cells affected by the 
mechanical impact.  Blebbing has been observed in other cell types in a process by which 
a decrease in membrane tension initiates a bulk flow of lipids and separation of the 
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plasma membrane from the underlying actin cytoskeleton (Charras et al. 2007; Charras et 
al. 2006; Keller and Eggli 1998; Keller et al. 2002).  Although mechanoporation induced 
by the mechanical insult may be one initiating factor for membrane blebbing (by directly 
decreasing membrane tension through the formation of holes/tears), subsequent events 
such as oxidative stress, increased intracellular pressure, cytoskeletal alterations, and 
sodium influx may also cause post-SCI blebbing as observed in other cell types 
(Cunningham 1995; Marin-Castano et al. 2005; Rentsch and Keller 2000; Shi et al. 
2005).  Plasma membrane blebbing has been associated with apoptosis and necrosis 
(Barros et al. 2003; Laster and Mackenzie 1996; Mills et al. 1998; Tomiyoshi et al. 
2004), but bleb formation does not necessarily lead to cell death (Hiruma et al. 2007; 
Marin-Castano et al. 2005; Shi et al. 2005).  Future work should be aimed at a better 
understanding of the causes and effects of membrane blebbing and its relationship to 
plasma membrane disruptions. 
Although plasma membrane damage has been observed in many models of 
traumatic CNS injury (Farkas et al. 2006; Geddes-Klein et al. 2006; Geddes et al. 2003; 
LaPlaca et al. 2007; Povlishock and Pettus 1996; Prado et al. 2005; Shi et al. 2000; Shi 
and Whitebone 2006; Whalen et al. 2007), the fate of cells experiencing membrane 
rupture remains unclear.  Although plasma membrane failure may be indicative of 
necrotic cell death, permeable cells do not necessarily die at acute time points (Geddes-
Klein et al. 2006; Guzman et al. 2001; Prado et al. 2005; Stroetz et al. 2001).  Some cell 
types have been shown to survive much larger tears in the plasma membrane, most 
notably up to 1 µm2 in sea urchin eggs with no evidence of cellular dysfunction (McNeil 
et al. 2000). Although the fate of cells experiencing membrane damage after CNS trauma 
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remains rather elusive, previous studies have correlated axonal membrane permeability 
marker uptake after CNS injury with irregular morphology (Kilinc et al. 2007; Stone et 
al. 2004) and abnormal electrophysiology (Prado et al. 2005; Shi and Whitebone 2006).  
In neuronal somata, acute plasma membrane permeability after traumatic brain injury has 
been correlated with cell death after cortical contusion (Whalen et al. 2007), but other 
reports utilizing a model of diffuse brain injury have found no strong correlations 
between dye uptake and morphological changes, fluorojade staining, or calpain activity 
(Farkas et al. 2006; Singleton and Povlishock 2004).  It is therefore likely that plasma 
membrane defects can lead to a variety of cellular consequences depending on the 
magnitude and duration of damage.   
Conclusions 
 This study investigated the anatomical distribution of plasma membrane 
permeability changes occurring acutely after SCI.  Our results demonstrate that non-
specific plasma membrane tears /defects form occur as a result of mechanical impact, 
with increased impact force causing more extensive damage.  Furthermore, we observed 
that membrane damage of cell bodies within spinal cord grey matter are larger near the 
injury epicenter then decrease in size distally.  Axonal membrane defects, however, were 
not variable in size for the range of permeability markers tested.  Cellular uptake of 
permeability marker was associated with morphological changes indicative of blebbing 
and shrinkage, suggesting that breaches in the plasma membrane lead to cell death and/or 
dysfunction.  Collectively, these results provide an enhanced foundation for 
understanding acute SCI pathophysiology and may offer insights for developing more 
mechanistically-driven treatment strategies. 
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Table 2.1.  Permeability markers used to assess plasma membrane damage.  Cellular 
uptake of three different fluorescent aldehyde-fixable molecules was quantified at 10 
minutes following acute spinal cord injury.  Dextran radii were approximated according 
to the equation r = 0.488MW0.437 (to account for its chain-like configuration), whereas the 
radius of Lucifer yellow was calculated using the equation r = 0.421MW0.427 (which 
assumes a globular conformation).  These equations are based on a previous study in 
which the relationship between molecular weight and size was derived from experimental 
data examining particle movement across biological membranes (Oliver et al. 1992).  
Note that dextran size is reported as an average but actually contains a range of molecular 
masses. 
 
 
Permeability marker Molecular size (Da) Molecular radius (nm) 
Lucifer yellow 457 0.6 
FITC-conjugated dextran 3,000 1.6 
FITC-conjugated dextran 10,000 2.7 
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Figure 2.2. Lucifer yellow uptake as a function of injury severity.  A dye exclusion 
assay was used to characterize plasma membrane damage 10 min following sham surgery 
(A) or contusion SCI with an impact force of either 100 kdyn (B), 150 kdyn (C), or 200 
kdyn (D).    Images shown here were taken from representative sections 2mm caudal of 
the epicenter.  Quantification of cellular uptake in the gray matter indicated that the 
rostral-caudal extent of plasma membrane damage increased with the severity of the 
injury (mean ± standard deviation; *p<0.05 compared to sham, †p<0.05 compared to 100 
kdyn; n=4-5 per group).  Scale bar = 50 µm.  
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Figure 2.3. FITC-dextran uptake in cell bodies within gray matter.  The number of 
cells permeable to 3kDa FITC-conjugated dextran (3dex) and 10kDa FITC-conjugated 
dextran (10dex) was quantified within tissue sections taken at discrete distances from the 
injury epicenter (n=3-4 per group; mean ± standard deviation).  Results demonstrate 
acute SCI-induced permeability marker uptake of 3dex and 10dex after moderate injury 
(B and C, respectively) compared to sham controls (A) as a function of distance from the 
injury epicenter.  More extensive uptake of the 3dex molecule was observed compared to 
10dex, indicating that membrane defects of larger size are located proximal to the injury 
epicenter while smaller membrane tears extend distally.  Images shown are confocal 
reconstructions at 1mm caudal of the epicenter.  Scale bar = 40 µm. 
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take up the fluorescent dye, whereas other neighboring cells became 3dex-positive.  Most 
permeable cells were comprised of a dense, dextran-filled cytoplasm surrounded by a less 
dense layer of fluid that did not fill with the fluorescent dextran molecule (arrows, A-I).  
The majority of dextran-impermeable cells did not exhibit blebbing (G-L).  These results 
indicate that plasma membrane damage is associated with pathophysiological alterations 
in cellular morphology.  Scale bar = 25 µm. 
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CHAPTER 3 
CITICOLINE AS A TREATMENT FOR SPINAL CORD INJURY: 
SUB-ACUTE ASSESSMENT 
 
 
Introduction 
 
 SCI is a debilitating condition that affects and estimated 12,000 Americans each 
year, but there is currently no reliable treatment (for review see (Baptiste and Fehlings 
2007)).  Use of high dose methylprednisolone, the current standard of care, has raised 
controversy because it has shown only modest benefit and may even cause harm to 
patients (Hall and Springer 2004; Hurlbert 2000; Sayer et al. 2006; Young and Bracken 
1992).  It is therefore necessary to investigate new therapeutic approaches for reducing 
morbidity and mortality caused by SCI. 
 In the previous chapter, we demonstrated that SCI contusion causes the plasma 
membrane to rupture, allowing molecules at least as large as 2.7nm in radius to enter the 
cell.  We and others have postulated that plasma membrane damage is a major 
contributor to cell death and dysfunction as well as neurological impairments.  Under 
normal physiological conditions, the plasma membrane serves as a barrier between the 
cytosol and the extracellular fluid.  Disruption of this barrier would be expected to 
destroy cellular homeostatic mechanisms and lead to death, electrophysiological 
dysfunction, and/or activation of aberrant signaling pathways.  Plasma membrane 
compromise can occur immediately after injury due to mechanical disruption (as shown 
in Chapter 2 as well as other reports (Choo et al. 2007; Shi et al. 2000; Shi and Pryor 
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2002; Shi and Whitebone 2006)), but can also persist up to several weeks (Shi 2004). 
Mechanisms causing persistent membrane damage are largely unknown but may be 
related to the state of the post-injury environment, which could either prevent the cell 
from resealing or increase the amount of damage. 
A decrease in phospholipid levels has been observed after SCI (Demediuk et al. 
1989a; Faden et al. 1987), supporting the hypothesis that persistent plasma membrane 
compromise may be due to abnormal phospholipid metabolism.  Loss of phospholipids 
can occur through lipid hydrolysis (mediated by phospholipase A2 [PLA2] activity) or 
lipid peroxidation (mediated by free radicals).  Free radical-induced damage has long 
been hypothesized to be a major mechanism involved in the pathophysiology of SCI (for 
review see (Braughler and Hall 1989; Hall and Braughler 1986; McCall et al. 1987), and 
more recent studies have shown that PLA2 levels also increase after injury (Liu et al. 
2007; Liu et al. 2006).  Loss of phosphatidylcholine (PC), the most abundant molecule in 
the plasma membrane of mammalian cells, is undoubtedly important in maintaining 
homeostasis.  In fact, loss of PC through inhibition of the citicoline pathway is sufficient 
to cause cell death under normal culture conditions in vitro (Cui and Houweling 2002; 
Cui et al. 1996).  Given the importance of maintaining PC and the fact that SCI causes 
the destruction of this molecule, we investigated a treatment strategy intended to restore 
PC levels and ultimately enhance post-SCI outcome. 
More specifically, we explored use of citicoline as an agent for facilitating 
membrane repair after SCI.  Citicoline is the precursor to PC and has been shown to 
increase phospholipid levels in models of CNS trauma and disease (Adibhatla et al. 2004; 
Adibhatla et al. 2006; Rao et al. 2000; Weiss 1995).  In addition to promoting PC 
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synthesis, citicoline also prevents its loss (Adibhatla and Hatcher 2003; Arrigoni et al. 
1987; Dorman et al. 1983; Trovarelli et al. 1981; Trovarelli et al. 1982a).  Sparing of PC 
has been attributed to a citicoline-mediated reduction in PLA2 activity (Adibhatla and 
Hatcher 2003; Adibhatla et al. 2006; Arrigoni et al. 1987).  Previous work has shown that 
PLA2 activation occurs when cells are permeabilized (Bauldry et al. 1996; Yawo and 
Kuno 1985) and that its activation can enhance membrane permeability (Maher et al. 
2007a; Maher et al. 2007b; O'Regan et al. 1996; Pratt et al. 2005).  Attenuation of PLA2 
can improve membrane integrity by reducing phospholipid hydrolysis and lipid 
peroxidation, since arachidonic acid created by PLA2 hydrolysis leads to oxidative 
damage.  PLA2 activity is elevated after SCI and has been postulated to be a major player 
in the resulting pathophysiology (Liu et al. 2006).   
In addition to stabilizing the membrane, citicoline’s ability to attenuate PLA2 
activity may have considerable benefits for post-SCI outcomes.  PLA2 serves as a major 
point of convergence for multiple signaling pathways involved in cellular responses 
including apoptosis, differentiation, membrane trafficking, and proliferation (for review 
see (Farooqui et al. 2006; Olivas and Noble-Haeusslein 2006)).  Rampant activation of 
PLA2 after SCI can lead to unchecked activation of these cell signaling pathways, 
causing cell death and/or dysfunction.  Notably, it has been demonstrated that 
experimental activation of PLA2 in the intact healthy rat spinal cord is sufficient for 
inducing paralysis and histological lesions that are comparable to the effects of SCI (Liu 
et al. 2006).   
By promoting membrane repair through a variety of mechanisms (increasing PC 
synthesis as well as decreasing PLA2 activity and free radical production), citicoline is 
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expected to facilitate plasma membrane resealing and enhance post-SCI outcomes.  
Numerous animal and clinical studies support the rationale of using citicoline as a 
treatment for SCI.  It has been shown to be safe for human use and effective as a 
treatment in animal models of CNS diseases and disorders (Barrachina et al. 2003; 
Baskaya et al. 2000; Cakir et al. 2005; Clark et al. 1997; Davalos et al. 2002; Yucel et al. 
2006).  No notable side effects have been observed, making it an appealing alternative to 
methylprednisolone therapy or a complement to lower dosing of methylprednisolone.  
Citicoline is currently approved for human stroke treatment in over 70 countries around 
the world and is now undergoing clinical trials in the United States.   
When administered after SCI in animals, citicoline has been shown to reduce lipid 
peroxidation, promote tissue sparing, and enhance functional recovery (Cakir et al. 2005; 
Yucel et al. 2006).  However, citicoline-mediated membrane resealing has not been 
directly assessed after SCI or in any other model of neurological dysfunction.  Therefore, 
although citicoline has been shown to reduce some potential causes of membrane 
compromise, it is currently unknown whether the drug is actually able to restore plasma 
membrane integrity.  In addition, citicoline-mediated alterations in PLA2 activity have 
not been explored in a model of SCI, even though this has been proposed as the primary 
mechanism of action after stroke and traumatic brain injury (Adibhatla et al. 2002; 
Arrigoni et al. 1987).   Due to this gap in the knowledge, we investigated the membrane 
stabilizing properties of citicoline (using a dye exclusion assay as a direct measure) and 
its effects on PLA2 activity in a rat contusion model of SCI.  We hypothesized that 
citicoline would promote membrane resealing, attenuate PLA2 activity, and reduce the 
size of the lesion. 
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Methods 
Surgical procedures 
All experiments were conducted according to methods approved by the Georgia 
Tech Institutional Animal Care and Use Committee (protocol A05003).  Moderate SCI 
was induced in adult male Sprague-Dawley rats (350-450g, total n=27) as described in 
detail elsewhere in this dissertation (Appendix A).  Briefly, animals were anesthetized 
with 50 mg/kg Nembutal (IP), and isoflurane was used as a supplement when necessary.  
Surgical procedures were conducted using aseptic technique.  Laminectomy was 
performed at T10 vertebral level, and then a force of 150 kdyn was imparted to the 
exposed spinal cord.  Muscle was sutured together and skin was stapled in order to close 
the wound.  Post-operational monitoring included bladder expression and maintenance of 
hydration until the time of sacrifice.  
Citicoline (500 mg/kg in saline, IP) was administered immediately and 3h after 
SCI and then once per day thereafter.  This dose was chosen according to a previous 
study demonstrating that prolonged high dose administration of citicoline was more 
effective than lower doses or less frequent delivery (Schabitz et al. 1996).  This dose is 
commonly used in studies conducted in animal models of ischemia (Adibhatla and 
Hatcher 2003; Krupinski et al. 2002).  Furthermore, clinical studies utilizing citicoline 
have administered high doses once daily (although much lower than those given in 
animals) (Clark et al. 1997; Clark et al. 2001).  All other animals received injections of 
the vehicle (saline) in order to control for the effect of fluid administration as well as any 
effects of the injection procedure. 
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Assessment of cPLA2 activity 
 
 cPLA2 activity was measured at 24h post-injury, a time point that has previously 
been shown to have elevated levels of PLA2 (Liu et al. 2007; Liu et al. 2006).  In 
addition, 24h allows enough time for citicoline to reach the CNS tissue (Lopez-Coviella 
et al. 1995) and provided greater attenuation of PLA2 activity compared to more acute 
time points after an ischemic insult (Adibhatla et al. 2006).  Experimental groups (n=4 
per group) included sham, injured animals receiving citicoline treatment, and injured 
animals receiving vehicle treatment.  Rats were anesthetized with Nembutal and then 
transcardially perfused with cold heparinized saline (0.16 mg/ml).  A 1cm piece of spinal 
cord tissue was extracted as quickly as possible (within 3-4 minutes) and placed in cold 
buffer (50 mM HEPES containing 1mM EDTA; 5ml per gram of tissue).  Tissue was 
mechanically homogenized on ice then centrifuged at 10,000g for 15 min at 4ºC.  
Supernatant was collected and stored at -80ºC until the assay was performed.  
PLA2 activity was assessed with a commercially available kit (Cayman Chemical 
Catalog # 765021; Ann Arbor, MI).  Techniques were performed according to the 
manufacturer’s instructions.  Quantitative assessment of PLA2 activity is based on the 
reaction of the enzyme with the synthetic substrate arachidonyl-thio PC.  PLA2 
hydrolyzes the arachidonyl thioester bond to release a free thiol group, which can then be 
detected through a reaction with DTNB (5,5’ dithio-bis(2-nitrobenzoic acid), also known 
as Ellmans’ reagent).  
Two main subtypes of PLA2 are present in biological tissues (secretory [sPLA2; 
14kDa] and cytosolic [cPLA2; 85-110 kDa]) and can be measured by this assay; 
however, samples were centrifuged in filter device with a 30kDa cutoff in order to obtain 
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a sample containing only cPLA2.  We chose to assess cPLA2 activity because it shows 
much greater specificity for phospholipids containing arachidonic acid in the sn-2 
position.  This is significant for the pathophysiology of SCI because arachidonic acid 
metabolism leads to the formation of free radicals and is known to be a major player in 
secondary injury cascades (Clark et al. 1995; Farooqui et al. 2006).  Furthermore, cPLA2 
is prevalent in CNS tissue (Ong et al. 1999) and is up-regulated after SCI (Liu et al. 
2006). 
All samples were run in multiples of 2-3, depending on the volume available after 
centrifugation.  Samples were incubated for 1h in arachidonyl-thio PC substrate at room 
temperature, and then 10 µl of DTNB/EGTA solution was added to each well and 
incubated for 5 minutes.  Absorbance was measured at 405 nm wavelength using a plate 
reader.  Measurements were normalized to the total protein concentration within the 
sample used in the assay using a bicinchoninic acid (BCA) assay (Pierce Biotechnology, 
Rockford, IL).  Comparisons were made using one-way ANOVA followed by Tukey’s 
pairwise comparisons. 
Histological assessments: plasma membrane damage and lesion volume 
 Rats were randomly divided into 3 experimental groups: sham, injured receiving 
citicoline treatment, and injured receiving saline treatment.  Lesion volume and plasma 
membrane damage was assessed in animals euthanized 3 days post-SCI.  This time point 
was chosen after a pilot study was conducted in which a dye exclusion assay was 
performed at 1d, 3d, and 7d post-SCI (n=1-2 per time point, data not shown).  The 1d 
post-SCI time point was ruled out because it did not allow for reliable quantification of 
permeable cells due to a large amount of tissue debris caused by the injury.  No 
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noticeable differences were observed at 3d and 7d, so the most acute time point of the 
two was chosen for this study in order to be most time and cost efficient.  The study 
began with n=5 per group.  However, 2 animals were excluded from the citicoline group 
(one animal was a statistical outlier when lesion volume was measures [Grubbs’ test], and 
one animal was given citicoline that was not properly stored overnight).   
 To perform the dye exclusion assay, rats were anesthetized with a low dose of 
Nembutal (40 mg/kg) on day 3 post-SCI.  A low dose was required to reduce the risk of 
animal death during the surgical procedure, as this had been observed in other 
experiments when surgery was performed on animals that had undergone a prior surgical 
procedure (Chapter 4).  Isoflurane was used as a supplemental anesthetic when needed.  
Permeability marker (FITC-conjugated 3kDa dextran [3dex]) was injected into the 
cerebrospinal fluid as previously described in this manuscript (Chapter 2).  3dex was 
selected because it was the most sensitive dye in the previous study (Chapter 2), detecting 
both cell body and axonal plasma membrane damage with minimal sham uptake.  Briefly, 
the animal was mounted on a stereotaxic apparatus and the atlanto-occipital membrane 
was punctured.  A catheter was inserted intrathecally and 3dex was injected (25 mg/ml in 
saline, 15 µl over 10 minutes).  Three hours later, rats were heavily anesthetized with 
Nembutal and then transcardially perfused with PBS followed by 4% paraformaldehyde 
and 0.1% gluteraldehyde.  Tissue was cryoprotected in sucrose, frozen in OCT, and 
sectioned longitudinally. 
 
Plasma membrane damage assessment 
 
Axonal plasma membrane permeability was assessed in citicoline and vehicle 
groups by a blinded observer.  Slides were selected in random order and the level of 
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permeability was ranked on a scale from 0 to 5 (higher score corresponding to more 
permeable cells).  Two adjacent sections at 200 µm increments were assessed for each 
animal.  Values obtained from all slides were then averaged to generate one score per 
animal, and groups were compared using a t-test.  
In order to visualize the morphology of permeabilized axons, sections were 
immunostained with an antibody specific for neurofilament-160 (NF-160) and imaged at 
40x using confocal microscopy (Zeiss LSM 510).  Immunohistochemistry was performed 
according to the protocol described in Chapter 2.  Briefly, sections were rinsed in PBS 
and then blocking/permeabilization was performed for 1h at room temperature (8% goat 
serum and 0.8% Triton X100 in PBS).  Sections were incubated in primary antibody 
(1:100; Sigma NF264) overnight at 4ºC, rinsed thoroughly in PBS, and then incubated in 
Alexa 568 goat anti-mouse secondary antibody (1:250; Invitrogen) for 2h at room 
temperature.  A negative control subjected to all solutions except primary antibody was 
used to determine whether staining was specific for NF-160.  Sections were rinsed then 
coverslipped using aqueous mounting medium. 
 
Determination of lesion size  
 
The volume of the lesion was compared in citicoline-treated rats and vehicle controls 
at 3 days post-SCI.  Two adjacent sections were stained with hematoxylin and eosin at 
200 µm increments.  The Nissl-free area within each section (outlined in Figure 3.4) was 
calculated using StereoInvestigator software, and the average of two adjacent sections 
was taken.  If more than one Nissl-free area was found within the same section, those 
areas were added together to obtain a measure of the total area at that location.  The area 
between experimentally measured points was estimated using a linear regression, and 
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then these values were used to approximate the lesion volume.  Groups were comparing 
using a t-test. 
Results 
cPLA2 Assay 
 cPLA2 activity was assessed in spinal cord homogenates taken 24h post-injury 
from sham as well as injured animals treated with citicoline or vehicle (Figure 3.1).  SCI 
caused an approximately 2-fold increase in cPLA2 activity.  Citicoline treatment 
decreased the average cPLA2 activity levels to be statistically the same as sham, but it 
was also not significantly different from untreated injured animals.  Sample size 
calculation using this data set revealed that 22 animals per group would be required to 
determine if there was a statistically significant difference between injured animals 
receiving vehicle and those receiving citicoline (power = 0.8, α = 0.05). 
Plasma membrane permeability 
 Axonal permeability was enhanced in injured animals compared to sham controls 
(Figure 3.2).  At this time point (3d post-SCI), 3dex uptake was minimal within cell 
bodies and was not noticeably different from sham; therefore our outcomes were based 
solely on axonal permeability. The morphology of permeable cells was heterogeneous 
and depended largely on the location relative to the lesion (Figure 3.2)  Some axons 
located relatively far from the injury site (Figure 3.2,  M-R) had a normal appearance, 
whereas others close to the lesion were fragmented or swollen on the ends (Figure 3.2, D-
L).  Immunostaining specific for neurofilament-160 (NF-160) showed colocalization with 
some but not all permeable axons. 
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A 5-point scale was used to assess the density of permeable axons in vehicle and 
citicoline-treated injured animals.  A high degree of variability was observed between 
animals (Figure 3.2, M-R). Comparison of axonal permeability marker uptake in 
citicoline-treated rats compared to vehicle control showed no difference between the 
groups (Figure 3.3).  The number of animals needed to obtain statistical power of 80% 
was calculated to be 22 per group (α = 0.05). 
Lesion volume 
 
Lesion volume was examined in histological sections obtained from citicoline and 
vehicle-treated injured animals to determine whether citicoline had a tissue-sparing 
effect.  Comparison showed no difference between citicoline-treated animals and the 
vehicle control (Figure 3.4).  Sample size calculation using this data set revealed that 22 
animals per group would be required to determine whether there is a statistically 
significant difference between the two groups (power = 0.8, α = 0.05). 
Discussion 
 
 This study assessed the ability of citicoline to reduce activation of the membrane-
destabilizing enzyme cPLA2, facilitate plasma membrane resealing, and attenuate gross 
tissue damage at sub-acute time points.  Citicoline is described as a membrane stabilizing 
agent and has been shown to promote plasma membrane repair and improve outcome 
following brain ischemia, but these properties have not been thoroughly explored in 
models of SCI (for review see (Adibhatla et al. 2002; Conant and Schauss 2004; Zweifler 
2002).  Only two studies investigating citicoline treatment for SCI have been published, 
and these have collectively shown that citicoline reduces lipid peroxidation and oxidative 
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stress at 24 hours and attenuates tissue damage and functional deficits at 6 weeks (Cakir 
et al. 2005; Yucel et al. 2006).  If citicoline will eventually be used in the clinic, however, 
it will be important to have a firm understanding of the treatment mechanisms involved.  
This can help with selection of patients (e.g., time post-injury and insult severity) for 
improved efficacy.  The main mechanisms of action in the stroke literature have been 
postulated to be restoration of membrane integrity as well as reduction in PLA2 activity 
(Adibhatla and Hatcher 2003; Adibhatla et al. 2006; Arrigoni et al. 1987), but this has not 
been evaluated in a model of SCI. 
 In this study we assessed cPLA2 activity at 24h post-injury.  Citicoline has been 
shown to decrease overall PLA2 activity in models of ischemic stroke (Adibhatla and 
Hatcher 2003; Adibhatla et al. 2006; Arrigoni et al. 1987).  Here we specifically 
examined cPLA2 activity instead of assessing all PLA2 isozymes.  This was done for 
several reasons.  In comparison to sPLA2, cPLA2 shows much greater specificity for 
phospholipids containing arachidonic acid, and this reaction is a key initiating event in 
inflammation and oxidative damage (for review see (Clark et al. 1995; Farooqui et al. 
2006)).  Furthermore, the spinal cord contains high levels of cPLA2 under normal 
conditions (Ong et al. 1999) and is up-regulated after SCI (Liu et al. 2006).   cPLA2 is 
therefore expected to be a large contributor to the cell death and damage occurring after 
SCI.  By examining this form of the enzyme (as opposed to determining the activity of all 
PLA2 enzymes), we expected to obtain more specific information regarding the 
mechanisms involved in SCI and citicoline treatment. 
Our results demonstrated that SCI significantly increased cPLA2 activity 
compared to sham controls.  This is a new finding that adds to the current knowledge of 
 50
secondary injury mechanisms, since only two previous studies have assessed PLA2 
activity after SCI and the assay was not specific for cPLA2 (Liu et al. 2007; Liu et al. 
2006).  These previous experiments detected a similar 2-fold increase in overall PLA2 
activity at 24h post-SCI, indicating that cPLA2 contributes at least a proportional amount 
of the overall increase in PLA2 activity levels.   
Treatment with citicoline decreased cPLA2 activity to levels statistically 
equivalent to both sham and vehicle-treated injured animals.  These data were interpreted 
to be encouraging even though there was not a statistically significant effect when 
animals receiving citicoline were compared to those not receiving the drug. Achieving a 
significant reduction in cPLA2 activity with citicoline treatment would be very difficult 
given the relatively small difference in the means between vehicle and sham and the 
amount of biological variability in the samples.  In order to achieve a statistically 
significant reduction in cPLA2 compared to vehicle controls, citicoline would have to 
almost completely prevent cPLA2 activation after SCI (which would be difficult at best). 
Although we chose to measure citicoline’s effects on cPLA2 activity based on 
sound logic, it is possible that evaluation of sPLA2 or overall PLA2 activity could show a 
larger treatment-mediated effect.  Citicoline has been shown to decrease overall PLA2 
activity in an animal model of stroke (Adibhatla et al. 2003).  It is unclear whether this 
effect was mediated through a reduction in sPLA2 or cPLA2 levels since the assay 
detected activity of both forms of the enzyme and both have been shown to increase in 
activity after an ischemic insult (Adibhatla and Hatcher 2003; Rordorf et al. 1991).  
Nevertheless, we interpreted the results of our cPLA2 assay to be somewhat promising, 
as citicoline treatment resulted in a modest decrease in activity levels. 
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In a separate group of animals, we explored plasma membrane damage induced 
by SCI and the effects of citicoline.  A fluorescent dye (3dex) was injected into the 
cerebrospinal fluid 3h prior to sacrifice.  3dex is normally cell-impermeant; therefore 
cellular uptake of the molecule indicates that the plasma membrane has been breached.  
Axonal uptake of the permeability marker 3dex was higher in injured animals (treated 
with citicoline or vehicle) compared to sham controls (Figure 3.2).  Permeable axons 
exhibited a variety of morphologies, ranging from a normal appearance to a pathological 
one (characterized by swelling and retraction bulbs).  Similar results have been observed 
in a previous study in which dextran uptake after SCI was associated with 
pathophysiological axonal alterations (Lu et al. 2001).  Bulb formation and axonal 
swelling have been observed after SCI and are postulated to precede degeneration 
(Anthes et al. 1995; Seif et al. 2007).   
 In addition to showing morphological alterations, permeable axons were 
inconsistently immunolabeled with NF-160.  Although this result may be attributed to 
technical difficulties associated with immunohistochemistry, it should be noted that more 
acute time points showed consistent colocalization of the permability marker with NF-
160 staining (Chapter 2).  Neurofilament loss has been observed after SCI, presumably 
due to activation of cytoskeleton-degrading enzymes (Banik et al. 1982; Banik et al. 
1997; Schumacher et al. 1999; Zhang et al. 2000).  In models of traumatic brain injury, 
alterations in plasma membrane permeability have been associated with neurofilament 
compaction and subsequent degradation (Okonkwo et al. 1998; Pettus et al. 1994).  
Cytoskeletal degradation may be indicative of the axon’s attempt to reseal, since 
disassembly has been shown to promote resealing by removing the barrier between 
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vesicles and the plasma membrane (Howard et al. 1999; Miyake et al. 2001; Shi et al. 
2000; Xie and Barrett 1991).  Our results show that plasma membrane damage 3 days 
post-SCI corresponds with neurofilament loss in some but not all cases.  Thus, the 
relationship between cytoskeletal membrane damage and plasma membrane compromise 
is complex but may be related to the extent and duration of axonal membrane 
compromise. 
 Our imaging results led us to speculate that axonal permeability is an initiating 
factor in neurofilament loss, swelling, fragmentation, and degeneration.  A subset of 
permeable axons appeared normal and others were damaged, which may represent 
populations of axons that are undergoing changes over time.  In addition, many 
permeable cells were found along the injury cavity and therefore are likely to undergo 
degeneration.  Thus, plasma membrane compromise may precede axonal degeneration.  
Future work tracking permeabilized axons over time would be necessary to investigate 
this hypothesis and determine if a cause-and-effect relationship exists. 
 Semi-quantitative comparison of permeability marker uptake in injured animals 
receiving citicoline or vehicle control showed no difference between the two groups.  We 
postulated that citicoline would reduce axonal permeability after SCI, but the data did not 
support this hypothesis.  A variety of experimental limitations and biological mechanisms 
may explain this result and are described in more detail below. 
Although a loss of phospholipids would certainly explain why permeability 
markers are able to enter axonal projections after SCI, we do not necessarily know that 
this is the mechanism responsible for increased plasma membrane permeability.  
Therefore, even if citicoline was able to increase phospholipid levels (which we did not 
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directly assess), it may not have necessarily changed the results obtained in the dye 
exclusion assay.  Alternative explanations for entry of the permeability marker into the 
cell membrane (other than a loss of phospholipids) include a failure in the vesicle 
docking mechanisms needed for endogenous repair (McNeil and Terasaki 2001; 
Schlicher et al. 2006; Terasaki et al. 1997) or an injury-induced alteration in protein 
activity involved in membrane turnover or resealing (e.g., calpain and annexin which are 
involved in membrane resealing) (Howard et al. 1999; Liu and Schnellmann 2003; 
McNeil et al. 2006; Shi et al. 2000; Yoo et al. 2003).  If these alternative explanations are 
responsible for persistent membrane damage, citicoline would not have been expected to 
have an effect on axonal dye uptake (even if it increased PC levels, which we did not 
assess).  Future work examining these mechanisms in a simplified model would provide 
valuable information regarding plasma membrane repair and resealing.  For example, 
experimentally manipulating the amount of PC molecules in vitro would provide 
evidence to determine whether membrane permeability could be related to a decrease in 
PC after SCI. 
 An additional possibility is that citicoline may have altered plasma membrane 
permeability at a time point we did not evaluate in this study.  The 3d time point was 
chosen because of the relative ease with which plasma membrane damage could be 
evaluated (although it remained a difficult task due to difficulty in distinguishing 
intracellular uptake from tissue debris and extracellular accumulation around blood 
vessels and myelin).  It is possible that citicoline may have changed the time course of 
membrane permeability (i.e., decreased the time required for resealing), but we only 
assessed one time point and therefore are limited in our ability to draw conclusions. 
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 In addition to measuring plasma membrane damage and cPLA2 activity, we also 
assessed the size of the lesion in citicoline-treated animals and vehicle controls at 3d 
post-SCI.  Results showed no treatment effect.  In a previous study, Yucel et al (2006) 
demonstrated that citicoline reduced the size of the injury cavity 6 weeks post-SCI.  
Although we did not achieve the same result in our study, differences may be attributed 
to variations in the dose administered or the time point selected.  It is possible that the 
time point we evaluated did not allow enough time for citicoline treatment to have a 
tissue-sparing effect.  Therefore, we evaluated this outcome at a more chronic time point 
in a subsequent study (Chapter 4). 
 In summary, we did not observe notable benefit of citicoline treatment at sub-
acute time points.  Although the data did not support our hypotheses, it is possible that we 
did not select appropriate time points or outcome measures.  In addition, it is plausible 
that citicoline improves outcome following SCI through mechanisms we did not test here.  
Therefore, in a subsequent study, we evaluated the effects of citicoline on functional 
recovery and longer-term tissue sparing in order to determine if the overall affects of 
citicoline treatment are beneficial. 
Conclusions 
 In this study we assessed the effects of citicoline as a membrane-stabilizing 
neuroprotective agent administered after SCI.  The rationale for investigating this 
treatment was based on a thorough review of the literature, which has shown beneficial 
effects of citicoline in numerous pre-clinical studies of neurological dysfunction.  Based 
on these previous reports and our knowledge of SCI pathophysiological mechanisms, we 
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hypothesized that citicoline would attenuate cPLA2 activity (24h post-SCI), plasma 
membrane compromise (3 days post-SCI), and lesion size (3 days post-SCI).   
Our data show that SCI causes a 2-fold increase in cPLA2 activity at 24h.  This 
finding is significant because it may prove to be an important target for pharmaceutical 
intervention, since cPLA2 is a major point of convergence for multiple signaling 
pathways.  In addition, we detected plasma membrane compromise at 3 days post-SCI 
utilizing a dye exclusion assay.  Permeability marker uptake was associated with 
morphological alterations (swelling, retraction bulbs, and fragmentation) as well as 
neurofilament loss. 
 Citicoline treatment caused a moderate decrease in cPLA2 activity (statistically 
the same as sham as well as vehicle control).  No effect on lesion volume or axonal 
permeability was observed.  The lack of citicoline-mediated effect could be a result of the 
experimental methods chosen (e.g., doses, time points, outcome measures) or treatment 
inefficacy.  Future work assessing a variety of time points, doses, and/or combinational 
therapies may support use of citicoline for treatment of SCI. 
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Figure 3.1: Effect of citicoline on cPLA2 activity at 24h post-SCI.  cPLA2 activity 
levels were assessed within spinal cord tissue homogenates taken 24 hours after SCI (n=4 
per group).  Injured animals receiving vehicle injections had significantly greater cPLA2 
activity than sham controls (p<0.05).  Citicoline-treated injured animals did not have 
statistically different PLA2 activity compared to sham (p=0.14) or vehicle controls 
(p=0.38).  Data is represented here as mean ± standard deviation. 
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Figure 3.3: Effect of citicoline treatment on axonal uptake at 3 days post-SCI.  3dex 
axonal uptake was evaluated in two adjacent sections at 200 µm increments throughout 
the thickness of the spinal cord.  Scores were assigned on a scale ranging from 0 to 5, 
with higher scores indicating a greater density of axonal permeability marker uptake.  
The average score for each animal was determined, and data were analyzed using a t-test.  
Results indicate that citicoline had no effect on axonal plasma membrane permeability 
(p=0.38).  Mean ± standard deviation, n=5 (vehicle) and n=3 (citicoline). 
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Figure 3.4: Effect of citicoline treatment on lesion volume at 3 days post-SCI.  The 
size of the injury cavity was measured in longitudinal sections stained with hemotoxylin 
and eosin.  A representative section is shown above with the area of the lesion outlined in 
black.  Citicoline treatment did not have a statistically significant effect on the size of the 
lesion at this time point (p=0.38).  Mean ± standard deviation, n=5 (vehicle) and n=3 
(citicoline). 
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CHAPTER 4 
CITICOLINE AS A TREATMENT FOR SPINAL CORD INJURY: 
BEHAVIORAL AND HISTOLOGICAL ASSESSMENT 
 
 
Introduction 
 Depending on the anatomical location and severity of the impact, SCI can result 
in functional impairments including sensory and motor paralysis, impotence, spasticity, 
bladder and bowel dysfunction, and neuropathic pain.  These consequences are 
particularly devastating because most individuals with SCI are otherwise healthy and 
under the age of 30 (Nobunaga et al. 1999).  Although SCI dramatically affects 
individuals, families, and society, there is currently no reliable treatment for reducing 
morbidity and mortality (for review see (Baptiste and Fehlings 2007; Kwon et al. 2004)).  
High dose methylprednisolone is the only treatment found to be clinically effective in 
controlled multi-center clinical trials and therefore has been considered the current 
standard of care when given within 8h of SCI (Bracken and Holford 1993; Bracken et al. 
1992; Bracken et al. 1997; Bracken et al. 1998).   However, the benefits provided by 
methylprednisolone are modest at best.  In fact, several clinical studies have shown no 
improvement when methylprednisolone was administered after SCI (George et al. 1995; 
Levy et al. 1996; Pollard and Apple 2003; Prendergast et al. 1994; Wang et al. 2004).  As 
a result of the questionable efficacy and serious side effects (e.g., severe sepsis, 
pneumonia, gastrointestinal disorders), use of methylprednisolone has become 
controversial (Coleman et al. 2000; Fehlings 2001; Hurlbert 2000; Lammertse 2004; 
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Sayer et al. 2006).  On one hand, these modest benefits may make a big difference in 
quality of life in these patients.  However, on the other hand, these individuals may suffer 
deleterious side effects but no improvements.  Therefore, there is a need to explore 
treatments that are safe, effective, and well-tolerated. 
Neuroprotective treatments are one strategy for reducing the damage caused by 
SCI.  Much of the cell death and degeneration caused by SCI does not occur immediately 
after impact, but instead accumulates over time in the following days, weeks, and months 
due to a variety of secondary injury mechanisms (for review see (Blight 2002; Dumont et 
al. 2001)).  Therefore, the prolonged time course of cell death and dysfunction provides 
an opportunity to deliver a therapeutic agent that prevents damage or augments repair. 
We have observed plasma membrane damage occurring in both the acute (Chapter 2) and 
sub-acute phases of SCI (Chapter 3) and subsequently investigated a treatment intended 
to augment endogenous membrane repair mechanisms.   
The membrane stabilizer citicoline offers an attractive strategy for reducing cell 
and tissue damage occurring after SCI.  Citicoline has been shown to improve functional 
outcomes and attenuate cell death in many models of traumatic CNS injury and disease 
and is currently undergoing clinical trials for stroke treatment in the United States 
(Adibhatla and Hatcher 2003; Adibhatla et al. 2002; Adibhatla et al. 2006; Arrigoni et al. 
1987; Cacabelos et al. 1993; Fioravanti and Yanagi 2004; Krupinski et al. 2002; Mir et al. 
2003).  Citicoline is postulated to reduce damage in the diseased brain by repairing the 
damaged plasma membrane components (increasing synthesis of phosphatidylcholine 
[PC] and preserving other membrane components) and also preventing membrane 
damage (decreasing PLA2 activity and free radical-induced damage) (Adibhatla and 
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Hatcher 2003; Adibhatla et al. 2003; Arrigoni et al. 1987).  Citicoline is safe for human 
use, and no notable side effects have been observed (Conant and Schauss 2004; Secades 
and Lorenzo 2006; Zweifler 2002).  
Citicoline has been extensively studied in models of stroke but has only recently 
been investigated as a treatment for SCI (Cakir et al. 2005; Yucel et al. 2006).  Cakir et 
al. (2005) assessed the effects of citicoline treatment within 48h after SCI, demonstrating 
improved locomoter function and reduced levels of lipid peroxidation.  In addition, Yucel 
et al. (2006) compared the efficacy of citicoline to that of methylprednisolone and a 
combination of the two drugs.  Citicoline reduced lipid peroxidation, nitric oxide levels, 
lesion size, and functional deficits. Treatment with citicoline was comparable to 
methylprednisolone treatment, but did not offer additional benefit when given in 
conjunction with methylprednisolone.  Although these studies show promise for 
citicoline treatment, more extensive pre-clinical research is needed to support clinical use 
and demonstrate reproducibility in various laboratories. 
Our previous studies (Chapter 3) demonstrated no citicoline-mediated effect on 
cytoplasmic PLA2 activity (24h post-SCI), plasma membrane permeability (3d post-
SCI), or lesion size (3d post-SCI).  However, the lack of effect may have been due to the 
outcome measures or time points selected.  Therefore, in this study, we proceeded to 
evaluate the longer-term histological and functional effects of prolonged high dose 
citicoline treatment.  Results obtained from these studies were intended to provide 
evidence to either support or oppose use of citicoline as a treatment for SCI, regardless of 
the mechanisms involved.   
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Materials and Methods 
Surgical procedures and treatment administration 
All procedures involving animals were approved by the Georgia Tech Institute of 
Animal Care and Use Committee (protocol A05003). SCI was performed according to 
methods described elsewhere (Appendix A).  Briefly, adult male Sprague-Dawley rats 
(365-430g) were anesthetized with Nembutal (50mg/kg, IP), and isoflurane (1-2%) was 
used as an anesthesia supplement when necessary.  A laminectomy was performed at 
vertebral level T10 to expose the underlying spinal cord.  Moderate SCI (150 kdyn 
impact force) was induced using the Infinite Horizons device.  Animals were randomly 
assigned to one of the following groups: sham (n=6), injured then treated with vehicle 
(saline; n=6), or injured then treated with citicoline (500 mg/kg of 200 mg/ml solution; 
n=6).  All animals received IP injections with either citicoline or saline immediately after 
injury, 3h after injury, and daily thereafter until sacrifice.  Shams and vehicle control 
animals received saline injections of an equal volume:weight ratio as the treated animals. 
Behavioral testing was conducted up to 36 days post-injury and animals were 
euthanized on day 37.  A permeability marker (10 kDa FITC-conjugated dextran [10dex]; 
Invitrogen) was injected into the cerebrospinal fluid three hours prior to sacrifice as 
previously described in Chapter 2.  Briefly, animals were anesthetized with 50 mg/kg 
Nembutal, and isoflurane (1-2%) was used when necessary.  An incision was made in the 
atlantooccipital membrane, and PE10 tubing was inserted into the intrathecal space.  
Fifteen µl of 10dex (2.5% in saline) was injected over 10 minutes.  A lethal dose of 
Nembutal was administered three hours following dye injection and animals were 
perfused with phosphate buffered saline (PBS) then cold 4% paraformaldehyde/0.1% 
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gluteraldehyde in PBS.  The vertebral column was excised and post-fixed for 24h.  Spinal 
cord tissue was dissected, immersed in sucrose, and then frozen in OCT.  Transverse 
sections at a thickness of 35 µm and 10 µm were generated using a cryostat for 
histological analysis. 
Behavioral outcome measures 
 Prior to injury, animals were placed on behavioral testing devices for mock trials 
until signs of fear (such as crouching, freezing, and frequent urination/defecation) were 
eliminated.  Pre-surgery scores were obtained for each animal on the BBB and plantar 
heat tests to ensure that each could perform the task and that none were statistical outliers 
that needed to be withdrawn from the study.  Animals were not placed on the grid prior to 
injury in order to prevent any training effects that may occur during repeated 
performance of a skilled task. 
 
Basso Beattie Bresnahan (BBB) open field locomoter 
 Animals were placed in an open field and encouraged to locomote for 4 minutes 
while blinded observers assigned a score ranging from 0 to 21.  As previously described, 
scores reflected a wide range of hindlimb function including joint movement, weight 
supported stepping, forelimb-hindlimb coordination, paw rotation, and toe drags (Basso 
et al. 1995).  A low score is considered a poor performance (limited hindlimb function) 
whereas a higher score is a reflection of greater function.  Each hindlimb was assigned an 
independent score and those scores were then averaged together to yield a single number 
at each time point.  Testing was conducted once a week for 5 weeks following injury.   
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 BBB open field scores were also converted to a subscore that has been shown to 
improve the sensitivity of the test (Lankhorst et al. 1999).  In this post-hoc analysis, the 
following are assigned to point values as follows: forelimb-hindlimb coordination (one 
point), trunk stability (one point), tail lift (one point), paw rotation at placement (0.5 
points per hindlimb), paw rotation at liftoff (0.5 points per himdlimb), and toe drags (one 
point per hindlimb).  Points were added together to create a single score with a maximum 
of 7 points.  BBB subscore was not generated at 1d post-SCI because injured animals 
were not consistently stepping at this time point. 
 
Grid walk 
 Animals were placed on an elevated wire mesh grid (4” x 2” spacing between 
rungs, 8”x 48”x 12”) for 3 minutes while a blinded observer counted the number of steps 
and the number of times the foot slipped below the grid.  Scores were calculated as the 
percentage of times the hindlimb stepped correctly (did not fall below the grid) relative to 
the total number of steps.  Testing was conducted at 29 and 37 days post-SCI. 
 
Plantar heat testing 
 Hyperalgesia was assessed using the Thermal Plantar Analgesia Instrument 
(Stoelting Co., Wood Dale, IL).  Animals were placed on a clear glass platform and a 
heat stimulus was applied to the plantar surface of the hindlimb using a near-infrared 
controller.  The latency for hindlimb withdrawal was quantified.  Great care was taken to 
control the environment in which testing was performed.  Only one animal was allowed 
in the room at a time to prevent high frequency communication between rats, and the 
platform was thoroughly cleaned between trials.  Each hindlimb was tested three times in 
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a random testing order and scores were averaged together.  At least 30 seconds was 
allowed between trials to prevent a sensory wind-up effect.  A decrease in the response 
latency was interpreted as a hyperalgesic effect, which has been observed in previous 
animal studies after SCI (Horiuchi et al. 2003; Mills et al. 2001). 
 
Statistical analysis 
 Each behavioral test was analyzed as a two-way repeated measures ANOVA 
followed by Tukey’s pairwise comparison (α=0.05).  Independent variables included the 
time point (day post-injury) and treatment (citicoline, sham, and vehicle).  The dependent 
variable was the behavioral score.  Scores more than two standard deviations from the 
mean were treated as outliers and were removed from the analysis. 
Lesion volume 
 Lesion volume was quantified using the Cavalieri method.  Thick sections (35 
µm) spaced 250 µm apart were stained with Hoechst and examined using 
Stereoinvestigator software (MBF Bioscience).  The area of the lesion was estimated by 
marking the points in a randomly placed grid (150 µm spacing) located within the lesion.  
These areas were then extrapolated to approximate the volume of the lesion according to 
the assumptions of stereology and the Cavalieri method (Mouton 2002).  
  The size of the cystic cavity was compared between vehicle and citicoline-treated 
animals (n=6 vehicle; n=4 citicoline).  Not all animals tested for behavior were used in 
this analysis because of a high accidental death rate during permeability marker injection.  
Death was likely a result of difficulties in controlling anesthesia during a second surgery 
under Nembutal anesthesia (Laura O’Farrell, PhD/DVM, personal communication). 
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Results 
Behavioral assessment of citicoline treatment following SCI 
 
BBB open field locomoter and BBB subscore 
BBB testing demonstrated an injury deficit at all time points assessed (Figure 4.1).  
Both citicoline and vehicle-treated animals performed significantly worse than sham 
controls, but no citicoline-mediated effect was observed.  Injured animals recovered to a 
score of approximately 15, which traditionally indicates that animals achieved weight 
supported stepping, forelimb-hindlimb coordination, and parallel paw placement at initial 
contact.  This score reflects deficits in paw rotation at lift-off, trunk stability, toe 
clearance, and tail position (Basso et al. 1995). 
 Although it is not reflected in the average BBB score, animals in this study 
typically fell into one of two categories: a score of 13 (frequent but not consistent 
forelimb-hindlimb coordination) or a score of 18 (consistent coordination but paw 
rotation during lift-off).  Scores between 13 and 18 represent consistent coordination but 
deficits in toe clearance; therefore, the BBB score average of 15 did not represent the 
population of animals tested in this experiment.  To address this mis-representation of 
data, we utilized a BBB subscore system, which has been previously published 
(Lankhorst et al. 1999).  Transformation of data into this subscore also revealed 
significant differences between sham and injured groups at all time points tested (Figure 
4.1).  Citicoline-treated rats performed significantly worse than vehicle controls on day 
29 post-injury.  This effect was not sustained on day 36.   
 Sample size needed to achieve statistical power of 80% with α = 0.05 on day 36 
was calculated using Sigma Stat 3.0 software.   At this time point, the difference in means 
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between vehicle and citicoline-treated animals was 1.1, and the average standard 
deviation was 1.7.  Results showed that 39 rats in each group would be needed to 
determine whether there was a statistically significant effect at this time point. 
 
Grid walk 
 Animals were placed on a wire mesh grid for three minutes and the number of 
footfalls relative to the total number of steps was quantified.  Results demonstrated that 
injured animals (citicoline and vehicle-treated) performed worse than sham controls at all 
time points assessed.  Citicoline-treated animals exhibited improved scores at 29 days 
post-injury, but this treatment-mediated effect was not observed on day 36 (Figure 4.2).   
 Sample size needed to achieve statistical power of 80% with α = 0.05 on day 36 
was approximated using Sigma Stat 3.0 software.   At this time point, the difference in 
means between vehicle and citicoline-treated animals was 4.79, and the average standard 
deviation was 12.8.  Results showed that 114 rats would be needed in each group to 
determine whether there was a statistically significant effect at this time point. 
 
Plantar heat  
 Plantar heat testing was conducted weekly up to 36 days post-SCI in order to 
quantify the withdrawal latency to a heat stimulus applied to the hindlimb. Although we 
expected a shorter response time in injured animals compared to sham controls, there 
were no statistically significant differences between any of the groups (Figure 4.3).  No 
signs of pain were observed during testing (vocalizations, attempts to escape, etc.); 
therefore, we concluded that contusion SCI did not induce hyperalgesia in these animals. 
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Histological assessment 
 The size of the lesion was estimated using the Cavalieri method in tissue sections 
obtained 37 days post-SCI.  SCI resulted in a large fluid-filled cyst at the center of the 
tissue, which is consistent with numerous studies utilizing a rat contusion model (Basso 
et al. 1996a; Scheff et al. 2003; Stokes et al. 1992).  Results demonstrated that citicoline 
treatment had no effect on the size of the lesion (Figure 4.4). 
 The power of the statistical test was 0.097, a number far below the desired power 
of 0.8.  Sample size was calculated to determine the number of animals needed per group 
to achieve statistical significance (difference between means = 2.24, average standard 
deviation = 2.85, desired power = 0.8, α = 0.05).  Approximately 27 rats would be needed 
to determine if there is a statistically significant effect.  
 
Assessment of permeability marker uptake 
 Plasma membrane damage was assessed at 37d post-SCI by injecting 10dex into 
the cerebrospinal fluid 3h prior to sacrifice, processing tissue for histology, and then 
visualizing axonal membrane damage with fluorescence microscopy.  As shown in Figure 
4.5, punctuate uptake of the FITC-conjugated dextran molecule was evident at this time 
point.  Tissue was stained with NF-160 in order to verify that permeability marker uptake 
was intra-axonal.  Some but not all dextran-positive regions colocalized with NF-160 
staining, providing evidence that the axonal membrane was compromised enough to 
allow influx of the dye.  Although we could not confirm definitively, the size and shape 
of regions of intense dextran not colocalizing with NF-160 suggested that axons with 
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neurofilament loss (a previously observed post-SCI response (Banik et al. 1982; Banik et 
al. 1997; Schumacher et al. 1999; Zhang et al. 2000)) also sequestered the dye. 
 
Discussion 
In this study, we examined the functional and histological effects of treatment 
with citicoline, a clinically appealing therapeutic agent.  Citicoline has been shown to be 
provide benefit in numerous studies of stroke (Adibhatla and Hatcher 2003; Adibhatla et 
al. 2002; Adibhatla et al. 2005; Clark et al. 2001; Davalos et al. 2002; Kakihana et al. 
1988; Krupinski et al. 2005; Trovarelli et al. 1982a) as well as CNS trauma (Baskaya et 
al. 2000; Cakir et al. 2005; Yucel et al. 2006).  Clinically, citicoline is an attractive drug 
because it targets a well-studied endogenous biochemical pathway (allowing better 
prediction of the effects) and has been shown to be safe. 
 Here we investigated the effects of daily administration of high dose citicoline.  
Functional outcome measures used in this study included two sensorimotor tasks (BBB 
and grid walk) as well as a measure of pain sensitivity (plantar heat).  SCI-induced 
deficits were observed in both the BBB and grid walk testing but not in the plantar heat 
test.  Interestingly, treatment with citicoline caused improved grid walk accuracy at the 
same time point that it decreased the BBB subscore.  Neither of these effects was 
observed at any other time point in this study.  Although these data are statistically 
significant, they cannot be considered biologically significant because the effects were 
fairly modest and not maintained over time.   
Although we did not observe notable citicoline-mediated behavioral effects, the 
discrepancy between treatment effects observed in grid walk and BBB testing are worthy 
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of discussion.  Differences between neurological mechanisms involved with each task 
may partially explain the apparent inconsistency in results.  BBB open field assesses 
normal locomoter patterns (which mostly involve local circuits at the spinal cord level in 
rats) while grid walk consists of a more skilled task (which would be expected to involve 
a larger contribution from higher order processing centers in the brain).  Therefore, these 
results suggest that citicoline may differentially affect these regions of the CNS.  
Additionally, these differences in outcome may be explained by variation in the 
motivating factors required for the test.  In the BBB, animals walk about the open field 
and are not punished or rewarded according to their performance.  In the grid walk, 
however, animals are inadvertently punished for missteps as they fall through the wire 
mesh.  Due to the added motivation to perform well on the grid, animals would be more 
likely to compensate or change patterns of movement.  Although we did not directly test 
cognitive function in this study, there is evidence that citicoline improves mental 
performance in animal models of Alzheimer’s disease and in humans suffering from 
dementia (Fioravanti and Yanagi 2004; Fioravanti and Yanagi 2005; Franco-Maside et al. 
1994).  Therefore, it is possible that citicoline-treated rats performed better on the grid 
walk due to improvements in higher level neurological processing.  In addition, citicoline 
treatment may have promoted sparing of corticospinal tracts and other circuits involved 
in skilled motor control and sensorimotor integration, thus improving performance on the 
grid. 
Plantar heat testing was utilized for assessment of pain hypersensitivity following 
SCI.  Nociceptive thresholds are commonly reduced following SCI in both humans and 
animals, causing unbearable pain that can sometimes lead to human depression or suicide 
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(Hao and Xu 2003; Horiuchi et al. 2003; Mills et al. 2001; Rintala et al. 1998; Stormer et 
al. 1997; Ullrich 2007).  Therefore, chronic pain is a clinically relevant outcome measure 
of high importance to humans with SCI and should be tested in pre-clinical studies.  In 
this study we did not observe an SCI-induced hyperalgesic response to the heat stimulus.  
Importantly, however, citicoline did not augment this response (in other words, citicoline 
did not cause pain in the animals).  Although it is possible that our detection methods 
were not sensitive enough to detect an SCI-induced deficit, we did not observe any signs 
of pain during the testing (i.e., vocalizations, attempts to escape, crouching, etc.).  This is 
consistent with the result we obtained when von Frey testing was performed (Appendix 
A); therefore the results are unlikely to be due to experimental artifact.  We therefore 
conclude that this contusion SCI model does not induce a hyperalgesic effect in our 
hands. 
In this study, treatment with citicoline after rat contusion SCI was beneficial in 
some behavioral outcome measures (grid walk) and detrimental in others (BBB 
subscore). In addition, citicoline did not reduce the size of the lesion.  One interpretation 
of these results is that citicoline is not an effective treatment of SCI.  However, studies 
conducted in other laboratories have shown enhanced functional recovery and increased 
tissue sparing with citicoline treatment after SCI in the rat (Cakir et al. 2005; Yucel et al. 
2006).  Yucel et al. (2006) demonstrated that citicoline was just as effective as 
methylprednisolone but did not offer additional benefit when used in combination.  We 
were unable to show a citicoline-mediated benefit in our studies.  This lack of treatment 
effect may be explained by experimental parameters (e.g., dosing, time points, outcome 
measures) or real biological inefficacy. 
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One notable difference in our study compared to those previously published by 
Yucel et al (2006) and Cakir et al (2005) is the selected dose.  In the current study, we 
chose to administer multiple high doses of citicoline (500 mg/kg given immediately after 
injury, 3h after injury, then daily thereafter until sacrifice).  In contrast, the published 
studies demonstrating functional improvement with citicoline treatment after SCI gave a 
slightly lower dose without prolonged treatment (300-400 mg/kg immediately after 
injury).  We chose to deliver such high doses because this amount has been shown to be 
more beneficial than lower doses or fewer doses after an ischemic insult to the rat brain 
(Schabitz et al. 1996).  In addition, previous work indicates that daily doses of 500 mg/kg 
for 42 days were needed to increase PC levels in normal animals (although the number of 
doses needed in the injured spinal cord is currently unknown).  Furthermore, human 
stroke clinical trials have utilized prolonged dosages of 500mg, 1000mg, and 2000mg 
given daily for six weeks (Clark et al. 1997).  We chose to deliver long-term high doses 
in order to be consistent with previous work conducted in other models of neurological 
dysfunction and based on the rationale that repeated dosing is necessary to increase PC 
levels in the CNS. 
It is not surprising that increasing the drug dose can reduce or even eliminate 
treatment effects.  Most pharmacological agents exhibit a dose-response curve with low 
and high extremes that are ineffective.  In this case, prolonged high-dose treatment may 
have exceeded the effective range of citicoline treatment and thus we did not observe 
improvements in functional recovery or lesion size.  The efficacy range of citicoline 
appears to be narrow and unpredictable, as clinical trials showed beneficial effects at 
500mg and 2000mg but not at an intermediate dose of 1000mg (Clark et al. 1997).  
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However, future work will be necessary to determine if the lack of efficacy we observed 
is due to a dose-response effect.  In other words, lower dose and/or shorter-term citicoline 
treatment would need to be directly compared to prolonged high-dose treatment.  Such 
experiments would also determine whether previously published reports are reproducible 
in other laboratories. 
An additional concern in this study is the sensitivity of the behavioral tests used.  
Hindlimb deficits occurring as a result of moderate contusion injury are subtle in nature, 
which may render small improvements difficult to assess.  Moreover, behavioral 
impairments observed in this study were less severe than previous experiments 
(Appendix A and others not shown) as well as other previously published studies (Basso 
et al. 1996a; Ferguson et al. 2004; Lankhorst et al. 1999; Scheff et al. 2003; Scheff et al. 
2002), which would make deficits more difficult to assess and decrease the likelihood of 
detecting a treatment effect.  In response to the lack of sensitivity in the testing methods, 
we have validated the use of the CatWalkTM in our laboratory (Appendix B).  The 
CatWalkTM is expected to improve the sensitivity of behavioral testing in future studies 
by providing a quantitative, objective, and reliable measure of gait parameters, thus 
improving the ability to detect treatment effects and distinguish sub domains of gait that 
may be differentially affected (Hamers et al. 2006; Hamers et al. 2001; Koopmans et al. 
2005).   
Another experimental limitation is the possibility that our study did not assess 
behavioral outcomes at time points that were long enough from the time of injury. One 
previous study did not observe citicoline-mediated effects until six weeks post-injury 
(Yucel et al. 2006), a time point we did not evaluate.  However, this study indicated a 
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steady increase in functional outcome in the citicoline-treated group prior to achieving 
statistical significance at six weeks, an effect we did not observe.  Furthermore, another 
study reported functional improvements with citicoline treatment as early as 24 hours 
after SCI (Cakir et al. 2005).  Although outstanding, it is rare that a treatment mitigates 
its effects so rapidly post-SCI; therefore it is unexpected that others would observe the 
same effect.   
Additional differences between this study and the previous may explain variations 
in the findings, including: injury severity (moderate in our study versus severe in the 
previous work), injury location (T10 in our study versus T7-T10 in previous work), 
surgical anesthesia (Nembutal/isoflurane in our study versus ketamine:xylazine cocktail 
in the previous work), citicoline vendor (Bio-Mol [Plymouth Meeting, PA] in our study 
versus Sigma [Steinheim, Germany] in the previous work), as well as rat strain and 
weight (Sasco Sprague Dawley 365-430 g in our study versus Wistar 210-280g in the 
previous work).  Future work investigating whether these parameters affect the efficacy 
of citicoline can lead to improved methods for selecting patients for treatment if citicoline 
is translated into clinical use (i.e., based on injury severity, injury location, and 
age/weight). 
 Although these logistical reasons and experimental caveats may explain the lack 
of citicoline-mediated improvement, it may also be explained by a lack of a real 
biological effect.  When citicoline is administered, numerous biochemical steps must be 
completed to produce PC (summarized in Figure 1.2).  If SCI decreases the activity of 
any enzymes involved in PC synthesis, precursors to PC will accumulate and the desired 
end product will not be synthesized.  Previous work has shown that exogenous citicoline 
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administration increases the activity of CTP: phosphocholine cytidylyltransferase in an 
animal model of stroke (Adibhatla et al. 2004; Adibhatla et al. 2006), but this has not 
been tested in SCI.  Since we did not directly measure PC or choline levels, we cannot 
draw conclusions on this possibility. 
Due to the potential of encountering rate-limiting enzymatic steps, others have 
sought to minimize the number of steps in the synthesis pathway.  More specifically, 
delivery of citicoline in liposomes has been shown to be more effective than delivery of 
the free drug (Adibhatla et al. 2005; Fresta et al. 1994).  When free citicoline is given IP 
as we did here, it is broken down into its components by the liver so that it can cross the 
blood-brain-barrier and then become resynthesized intracellularly (Trovarelli et al. 
1982b).  Therefore, delivering citicoline within a liposome would be expected to 
bypassing these steps in the PC pathway and thus increase efficacy.  Future work 
combining citicoline treatment with a drug that augments the necessary enzymatic 
activity may also improve the efficacy of citicoline treatment. 
One somewhat surprising finding from this work was that plasma membrane 
damage was evident at such a chronic time point (37 d post-SCI).  Since the plasma 
membrane plays an essential role in cellular survival and function, compromise of this 
structure is likely to be a major detriment to neurological outcome.  Future work 
examining strategies intended to facilitate membrane resealing may lead to an effective 
treatment for SCI. 
Conclusions 
 
 This study assessed the behavioral and histological effects of prolonged high-dose 
citicoline treatment.  Our results demonstrate minimal to no benefit of citicoline 
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treatment, as behavioral outcome measures were not able to detect sustained 
improvements and assessment of the lesion volume showed no treatment effect.  Long-
term high dose administration of citicoline, however, was not detrimental to post-SCI 
outcomes.  Future work designed to optimize citicoline dosing regimens or combine it 
with other therapies may show more promise for clinical application of citicoline 
following SCI. 
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Figure 4.1.  Assessment of citicoline-mediated effects on normal locomotion 
patterns.  Traditional BBB open field testing revealed no significant difference in 
hindlimb locomotion in animals treated with citicoline compared to vehicle controls.  
However, conversion of the BBB score to a subscore revealed that citicoline-treated 
animals performed worse than controls on day 29 post-injury.  This effect was not 
observed at any other time point. 
 
0
3
6
9
12
15
18
21
1 8 15 22 29 36
BB
B 
sc
or
e
Days post-SCI
BBB open field
Sham
Vehicle
Citicoline
0
1
2
3
4
5
6
7
8
8 15 22 29 36
BB
B 
su
bs
co
re
Days post-SCI
BBB subscore
Sham
Vehicle
Citicoline
*
 80
 
Figure 4.2.  Effect of citicoline on skilled hindlimb movements.  Animals were placed 
on a wire mesh grid and the number of footfalls relative to the total number of steps was 
quantified.  Treatment with citicoline increased placement accuracy on the grid at day 29 
but this effect was not observed on day 36. 
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Figure 4.3.  Evaluation of sensitivity to a stimulus.  A heat source was applied to 
hindlimbs and the withdrawal latency (time required for hindlimb removal) was 
quantified.  Although scores did not demonstrate a deficit in injured animals compared to 
sham, citicoline did not increase pain sensitivity.  
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Figure 4.4: Effect of citicoline treatment on lesion volume at 37 days post-SCI.  The 
volume of the injury cavity was estimated in transverse histological sections using the 
Cavalieri method (n=4 citicoline treated rats, n=6 vehicle controls).  Treatment with 
citicoline after SCI had no effect on the size of the lesion (p>0.05).  A representative 
lesion epicenter is shown on the right (scale bar = 500 µm). 
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CHAPTER 5 
CONCLUSIONS AND FUTURE WORK 
 
 
The incidence and long-term debilitating consequences of SCI make it a major 
socioeconomic concern.  Because there are no reliable clinically available treatments, 
there is a need to uncover and explore alternative mechanisms of cellular damage and 
dysfunction then target those mechanisms with rational treatment strategies.  
Accordingly, this research project was focused on achieving a better understanding of 
plasma membrane compromise occurring after SCI and investigating a treatment 
approach intended to augment membrane repair.   
Through a series of experiments utilizing a dye exclusion assay in an in vivo rat 
contusion model, we observed plasma membrane compromise at acute (within 10 min), 
subacute (3d post-SCI), and chronic (5w post-SCI) time points.  Our assessment of 
permeability marker uptake revealed that SCI causes immediate as well as persistent 
breaches in the plasma membrane that are large enough to allow the influx of normally 
cell-impermeant molecules.  Alterations in membrane permeability within neuronal cell 
bodies in the gray matter occurred in the acute phase but did not persist in the subsequent 
time points we assessed.  Cell bodies taking up the permeability marker at the 10 min 
time point often had a pathological appearance, including pericellular blebbing and cell 
shrinkage.  Axonal permeability changes, however, were observed at acute, sub-acute, 
and chronic time points.  Morphology of permeable axons was most extensively 
examined 3d post-SCI.  A subset of permeable axons adjacent to the lesion were 
fragmented and/or swollen, whereas others farther from the injury site had a normal 
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appearance.  These findings indicate that plasma membrane damage is linked with a 
variety of morphological alterations, which are potentially related to the size of the 
membrane breach and/or the amount of time that it is present.  
These results provide the foundation for future work examining the causes and 
effects of plasma membrane permeability after SCI.  For example, our results 
demonstrate that membrane damage persists for several weeks post-injury.  Although it is 
understood that the mechanical impact can cause immediate damage by physically 
rupturing the membrane, the factors causing longer-term damage are highly complex and 
not fully understood.  Future experiments performed in a more simplified in vitro axonal 
injury model would allow for well-controlled manipulation of certain variables in order to 
examine the major players that contribute to the loss of plasma membrane integrity.  
Potential mediators of membrane damage include a decrease in phospholipid synthesis 
(e.g., through decreased CTP: phosphocholine cytidyltransferase activity), increased 
phospholipid damage (e.g., through increased PLA2 activity or free radical production), 
and/or a failure to reseal (e.g., through blocking of vesicle fusion with the cell 
membrane).  These parameters could be experimentally altered by genetically modifying 
the cells or using pharmacological agents to either augment or block each variable 
individually.  Measuring the duration and extent of permeability increases due to these 
modifications can help elucidate their role and lead to a better understanding of the 
mechanisms involved.   
Our experiments also suggested that persistent plasma membrane compromise is 
associated with morphology consistent with axonal degeneration.  However, we did not 
explicitly show that there is a cause and effect relationship.  Future work aimed at 
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isolating plasma membrane permeability from other post-injury variable would be useful 
for examining this more closely.  For example, holes/tears of known sizes and duration 
time could be created in axons in vitro using a laser or a similar tightly controlled 
stimulus, and these cells could be tracked over time to determine the effects.  Varying the 
pore size, number of pores, and pulse duration could help determine the parameters that 
lead to pathological changes, thus allowing us to better define the critical cellular 
thresholds. 
 This research also investigated citicoline as a treatment intended to facilitate 
membrane repair and improve post-SCI outcomes.  Our data showed little to no benefit 
when citicoline was administered to rats at high doses and at frequent repeated delivery 
times (500 mg/kg given immediately and 3h after injury then daily thereafter).  We 
assessed a plethora of outcome measures (cPLA2 activity, plasma membrane 
permeability to 3kDa dextran, lesion volume, and a variety of behavioral tests).  
However, none of these experiments demonstrated a biologically significant treatment 
effect.   
Future experiments comparing the levels of citicoline, phosphatidylcholine (PC), 
and the intermediates in the synthesis process (see Figure 1.2) in sham, injured, and 
citicoline-treated injured rat spinal cords could be performed in order to allow a more 
complete interpretation of our results.  At present it is unclear whether citicoline was able 
to increase PC levels after SCI.  If citicoline was able to increase PC to levels equivalent 
to sham, we could infer that PC loss has minimal (if any) effect on plasma membrane 
permeability (at 3d post-injury), lesion volume (at 3d and 5w post-injury), or behavioral 
outcomes (up to 5w post-injury).  If, however, citicoline did not enhance PC levels, it 
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would be useful to know which step in the synthesis process was rate-limiting.  For 
example, an accumulation of choline would suggest that choline kinase activity limited 
the synthesis of PC.  This assessment could provide the opportunity to deliver 
combinational therapies to increase PC synthesis (e.g., delivering citicoline in 
combination with a choline kinase activator). 
Our results using citicoline as a treatment contradict previous reports showing that 
citicoline is beneficial as a treatment for SCI (Cakir et al. 2005; Yucel et al. 2006).  
However, these studies differed from ours in the dosing regimen administered (we 
administered immediate and daily doses, whereas previous reports delivered only a single 
bolus immediately after SCI).  Thus, one interpretation is that citicoline loses its efficacy 
when administered more frequently.  A study directly comparing these dosing regimens 
would be necessary to determine if this is the case.  Taken together, these findings 
indicate that clinical translation of citicoline treatment will require additional animal 
studies in various laboratories to verify efficacy, determine a dosing strategy (e.g., 
number of doses and time administered post-SCI), and define the conditions under which 
it provides a favorable outcome (e.g., varying injury severity).  If citicoline is determined 
to have a reliable treatment effect, such studies will facilitate essential planning for 
clinical trials.  The need for extensive pre-clinical studies should not be overlooked, since 
ill-planned clinical trials have plagued the field of neurotrauma for years and may have 
led to inconclusive results in some instances (Lammertse et al. 2007; Machado et al. 
1999; Sayer et al. 2006; Tolias and Bullock 2004). 
 Although citicoline was not efficacious in our studies, there is great potential for 
targeting plasma membrane compromise to treat SCI.  The plasma membrane plays a 
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fundamental role in maintaining cellular homeostasis.  Its integrity is crucial for all 
aspects of cell function; therefore the finding that SCI causes persistent membrane 
compromise may be significant for developing new treatment strategies.  Future work 
identifying the mechanisms compromising the plasma membrane may lead to the design 
and efficacy of novel therapies.  Although we have yet to find the “magic bullet” for 
curing SCI, this research may bring us one step closer to finding a clinically effective 
treatment. 
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APPENDIX A 
VALIDATION OF SPINAL CORD CONTUSION MODEL 
 
 
Introduction 
 
 Spinal cord injury (SCI) is most commonly initiated by fracture or dislocation of 
the spinal column, which results in tissue damage in the spinal cord parenchyma.  The 
mechanical impact causes displacement of bone fragments, intervertebral discs, or 
ligaments, resulting in transient compression or contusion of spinal cord tissue.   When 
mechanical forces surpass structural thresholds, cell death (necrosis) occurs and blood 
vessels become ruptured.  In addition, this mechanical perturbation sets into motion a 
series of events which includes many complex pathophysiological alterations such as 
blood-spinal cord-barrier breakdown, edema, inflammation, excitotoxicity, and apoptotic 
cell death (for review see (Dumont et al. 2001; Hagg and Oudega 2006; Hausmann 
2003)).  Collectively, these events result in the formation of a fluid-filled cystic cavity 
that gradually expands over the days, weeks, and months after injury. 
 The contusion SCI model mimics the transient compression of spinal cord tissue, 
as a brief mechanical impact is applied bilaterally to the dorsal surface of the exposed 
spinal cord.  When animals are injured at a mid-thoracic vertebral level (T10 in this case), 
they exhibit symptoms of SCI including hindlimb, trunk, and tail sensorimotor 
dysfunction.  In some cases, rodents also display other characteristics of SCI including 
neuropathic pain and a loss of bladder function.  The lesion created by the mechanical 
impact is similar to human SCI, characterized by a fluid-filled cystic cavity that expands 
over time then eventually stabilizes (for review of animal models see (Kwon et al. 2002)).  
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T10 was chosen as the injury location because it induces functional deficits that can be 
assessed with behavioral testing without causing unnecessary forelimb paralysis or 
respiratory dysfunction (which would be induced with a cervical injury).   
Although a variety of animal species and modes of injury have been used to study 
SCI, contusion injury in the rat is a commonly used animal model.  The first contusion 
model consisted of a weight dropped onto the spinal cord from a known height (Allen 
1911).  The severity of injury could be altered by dropping the weight from various 
heights, resulting in graded histological and functional effects (Black et al. 1988; Noble 
and Wrathall 1987; Wrathall et al. 1985).  Further technological advances in the field 
resulted in the creation of more sophisticated devices that induce a single rapid impact.  
The user can prescribe the severity of injury by altering the piston displacement (Stokes 
et al. 1992) or force (Scheff et al. 2003).  These devices are more consistent and 
reproducible compared to weight drop because they eliminate any bouncing that may 
occur.  In addition, feedback control allows the investigator to determine the actual force 
and/or displacement applied, which can then assist in ruling out instances when bone or 
other tissue was impacted inadvertently.   
We chose to use the commercially available Infinite Horizons device (Precision 
Systems and Instrumentation, Lexington, KY) in these studies because of its widespread 
use in the field of neurotrauma research (thus allowing for direct comparisons between 
research groups) as well as logistical reasons (portability, ease of use, cost, etc.).  This 
device utilizes a piston driven by a servo-controlled motor to impact the spinal cord at a 
user-defined force.  This model has been previously characterized and has demonstrated 
behavioral and histological characteristics of human SCI (Scheff et al. 2003). 
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 The purpose of this study was to validate the SCI rat contusion model in our 
laboratory and establish behavioral outcome measures that can be used to assess potential 
treatment strategies.  Accordingly, we performed moderate contusion SCI (150 kdyn 
impact force) on rats and compared functional outcomes to sham and naïve controls.  Our 
results demonstrate that SCI resulted in measurable functional deficits and validate that 
the injury model used in our studies are similar to those previously published. 
Materials and Methods 
Surgical procedures   
All procedures involving animals were approved by Georgia Tech’s Institutional 
Animal Care and Use Committee.  Male Sasco Sprague-Dawley rats (300-400g, n=18 in 
total) were anesthetized with sodium pentobarbital (50 mg/kg IP).  Prior to surgery, rats 
were shaved, eye ointment was applied, and the local anesthetic Marcaine was 
administered (0.2cc, subcutaneous).  Skin was scrubbed with three applications of alcohol 
then chlorohexiderm.  An incision was made along midline, and the muscle overlying 
T10 vertebrae was removed.  In injured animals (n=8), the spinal cord was impacted with 
a force of 150 kdyn (Precision Systems and Instumentation, Lexington, KY).  Following 
injury, muscle was sutured and skin was stapled in order to close the wound.  Saline was 
administered to prevent post-operational dehydration (5cc, subcutaneous).  Shams (n=6) 
were subjected to all surgical procedures except for mechanical impact (to control for all 
surgical procedures including laminectomy). Naïve animals (n=4) received only 
anesthesia, pre-surgery preparation, and an incision along midline, which was necessary 
for keeping observers blinded to the identity of animals undergoing testing.  
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A strict post-operational care regimen was implemented to ensure ethical 
treatment of animals and reduce unnecessary pain and health complications.  Rats were 
weighed three times in the first week after surgery and once per week thereafter.  If rats 
lost 10% of their body weight, they were given a nutritional supplement until body mass 
was restored.  Bladders were expressed twice a day until voiding function was consistent 
for three consecutive days.  Hydration status was monitored daily in the first week with a 
gentle dorsal skin pinch.  Fluids were administered subcutaneously (saline, 5cc) if skin 
was slow to retract. 
Following behavioral testing, animals were euthanized via transcardial perfusion 
with phosphate buffered saline followed by 4% paraformaldehyde.  Spinal cord tissue 
was removed, post-fixed overnight, and then immersed in sucrose.  Tissue was frozen in 
OCT medium and stored at -80ºC. 
Behavioral assessment 
For approximately two weeks prior to surgery, animals were handled by 
researchers and placed in testing devices until signs of fear were no longer present 
(crouching/freezing, frequent urination and defecation, etc.).  All behavioral testing was 
conducted once a week up to 57 days after surgery, and observers were blinded.  The 
time of day for testing was kept as consistent as possible to reduce variability.  As 
recommended by others, a range of behavioral activities were tested, including 
spontaneous locomotion, skilled motor performance, and sensory function (Basso 2004; 
Muir and Webb 2000).  Testing was conducted once prior to surgery to ensure that each 
rat was able to perform within the normal range of hindlimb function.  Scores more than 
two standard deviations from the mean were treated as outliers and removed from the 
analysis.  Groups were compared using two-way repeated measures ANOVA followed by 
Tukey’s pairwise comparisons (α = 0.05). 
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Basso Beattie Bresnahan (BBB) open field locomoter  
BBB testing was performed according to previously described methods (Basso et 
al. 1995).  Briefly, each animal was placed in the open field for four minutes, and 
hindlimb function was scored by two observers based on parameters such as joint 
movement, weight-supported stepping, coordination, paw rotation, and trunk stability.  
Possible scores ranged from 0 to 21, with higher scores corresponding to greater hindlimb 
function.  Scores obtained for the left and right hindlimb were averaged together since the 
injury was bilateral.  Although this scoring system is ordinal, the ANOVA was deemed 
an appropriate statistical test due to its robust nature (Scheff et al. 2002).  In addition, 
others have noted that the scale is ordinal in the scoring range we observed (Ferguson et 
al. 2004).  
 
Grid walk 
Animals were placed on an elevated wire grid (4” x 2” spacing between rungs, 
8”x 48”x 12”) for three minutes and encouraged to locomote with gentle prodding.  
During the testing session, the total of number of steps taken, the number of times the 
hindlimbs missed a rung, and the number of accurate steps were quantified and recorded.   
Data were expressed as the percentage of accurate steps relative to the total number of 
steps. 
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Von Frey Testing 
The von Frey sensory test was used to evaluate the recovery of sensory function.  
Typically, animals with more severe spinal cord injuries will be more sensitive to a 
normally innocuous stimulus (Hutchinson et al. 2004; Lindsey et al. 2000; Mills et al. 
2001; Yoon et al. 2004).  Animals were placed in a clear plastic box above a wire mesh 
grid (¼” x ¼”) and given a food reward (fruit cereal) to distract the animal during testing.  
In addition, marks were applied to the hindpaw using a permanent marker in order to 
maintain a consistent location of stimulus application. A known force was applied to the 
plantar surface of the hindpaw with a set of Semmes-Weinstein monofilaments (Stoelting 
Co., Wood Dale, Illinois).  Testing was conducted only when the animal was eating in an 
attempt to normalize the stress level and to prevent responses due to visualization of the 
monofilament.  A positive reaction to the stimulus was scored if the animal responded by 
lifting the hindlimb, and the next smallest monofilament was used.  If no response was 
observed, the next largest monofilament was used.  This process continued until 20 
consecutive stimuli were conducted per hindlimb.  At least five seconds was allowed 
between trials to prevent a sensory wind-up response.  The score was reported as the 
lowest force that caused a response >50% of the time, and the threshold values for the 
right and left hindlimb were averaged together.  Testing was restricted to animals 
exhibiting weight support in the open field because otherwise the monofilament lifted the 
hindlimb before a response was elicited.  Thus, injured animals were not tested on day 
two and the number of injured rats undergoing testing was reduced on days nine (n=5), 
sixteen (n=7), and twenty-three (n=7). 
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Results 
BBB Open Field Locomotor 
 BBB scores revealed that spinal cord impact produced sustained deficits in 
locomotion (Figure A.1).  Specifically, animals receiving spinal cord impact performed 
significantly worse at all time points compared to sham and incision only/“naïve” rats.  
Thus, we can conclude that the mechanical impact (and not the surgical procedure of 
laminectomy) was responsible for alterations in locomotor function.  These results are 
comparable to those previously reported when moderate contusion injury was applied to 
the rat spinal cord (Basso et al. 1995; Lankhorst et al. 1999; Scheff et al. 2003). Injured 
rats averaged a score of approximately thirteen on the BBB scale, which signifies that 
recovery was limited to consistent weight supported stepping with frequent but not 
consistent forelimb-hindlimb coordination.  Observed deficits also included toe drags, 
rotation of the hindlimbs during locomotion, trunk instability, and inability to maintain 
the tail in an elevated position. 
Grid Walk 
 Grid walk testing resulted in significantly greater footfalls in injured animals 
compared to sham and naïve controls (Figure A.2).  Sham surgery did not alter grid walk 
performance compared to naïve animals, demonstrating that the surgical procedure was 
not detrimental to hindlimb function in this behavioral task.  Although it is difficult to 
directly compare our data to other published reports (due to slight variations with injury 
models and grid walk specifications, etc.), these results are similar to other reports in the 
literature using rat models of moderate contusion SCI (Dijkstra et al. 2006; Lankhorst et 
al. 1999; Metz et al. 2000). 
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Von Frey Testing 
 We explored hindlimb sensitivity to a tactile stimulus by performing von Frey 
testing.  This was considered an important outcome measures since neuropathic pain is a 
clinically relevant problem that dramatically affects human quality of life after SCI (and 
thus would be a useful outcome measure when assessing potential therapeutic agents).  
However, we did not observe an SCI-induced deficit in touch sensitivity at any of the 
time points assessed (Figure A.3). 
 Although it is quite possible that our injury model does not induce 
hypersensitivity, unforeseen errors in the testing methods may also explain our results.  
Pain testing must be carefully performed so that factors such as stress and environmental 
cues are carefully controlled, and it is possible that we may have overlooked an external 
factor that masked any injury-induced effects.  Some researchers perform testing with 
only one animal in the room to prevent communication between animals.  This high 
frequency communication can heighten the next animal’s sensitivity and thus alter the 
threshold for response.  It has also been noted that environmental factors such as 
temperature, relative humidity, and the surface the rat stands on can alter the properties of 
von Frey hairs and thus change the force applied (Andrews 1993; Pitcher et al. 1999).  
Such precautions were not taken in this study; animals were all placed in the same room 
where testing occurred and environmental conditions were not tightly controlled.  Lack of 
control of these factors may have caused the high degree of variability we observed. 
 Although these technical concerns may have led to erroneous results, some 
observations led us to believe that the injury simply did not induce hypersensitivity in the 
animals.  Naïve and sham animals were within the normal range (60-80g), indicating that 
methods were performed in a manner consistent with previous reports (Hutchinson et al. 
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2004; Lindsey et al. 2000).  Injured rats did not have an exacerbated response to the 
stimulus (vocalizations, spasticity, jerky reflexive movements, etc.), which would suggest 
that they did not perceive pain when the stimulus was applied.  Results obtained from a 
subsequent study (Chapter 4) further support this explanation, as we were unable to 
detect injury-induced hypersensitivity to a heat stimulus in this model. 
Discussion 
 Results obtained from this study demonstrated deficits in locomotor function and 
grid walk performance for at least eight weeks post-injury.  Importantly, sham surgery 
did not decrease performance on any task, demonstrating that surgical procedures 
(specifically laminectomy) did not inadvertently injure the spinal cord.  Von Frey testing 
revealed no SCI-induced hypersensitivity, which may be explained by absence of this 
phenomenon in our hands or limitations in the testing methods employed.  Overall, these 
results validate the SCI model used in the studies throughout this thesis, as the findings 
are similar to those previously reported. 
Contusion injury in the rat creates histological and functional deficits that closely 
mimic the human condition.  Rodent contusion injury results in a tissue response that 
starts with progressive hemorrhage and edema followed by a period of partial repair and 
regeneration and eventually results in a chronic lesion comprised of a fluid-filled cystic 
cavity surrounded by intact tissue (Dumont et al. 2001; Kwon et al. 2004; Rosenzweig 
and McDonald 2004).  These SCI-induced histological alterations are consistent with 
those observed in humans (Hayes and Kakulas 1997; Stokes and Jakeman 2002) and 
therefore provide a clinically-relevant experimental model to explore mechanisms and 
treatments.   
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In addition to the changes occurring within the tissue, we and others have shown 
that contusion SCI results in functional deficits that can be measured over time in an 
animal model.  This aspect of animal research provides a method for assessing recovery 
of neurological function, a clinically relevant outcome for persons with SCI.  The results 
obtained in this study demonstrate that we are able to perform contusion SCI in rats and 
assess behavioral outcomes.  Optimization of these methods was necessary before any 
new scientific research could be conducted.  Therefore, the findings presented here 
provide the foundation for performing the remainder of the experiments described in this 
dissertation. 
Although the contusion model is accepted by the scientific community as a 
clinically relevant model of SCI, there are some limitations that must be addressed.  SCI 
often occurs as a result of a traumatic injury (such as a motor vehicle accident) in which 
many other wounds may be inflicted.  In fact, approximately 50% of the SCI patients also 
sustain a brain injury (Macciocchi et al. 2004; Tolonen et al. 2007).  These concurrent 
injuries may alter the systemic response to SCI but are not modeled here.  In addition, 
exposure of the spinal cord by laminectomy allows for more reproducible injury; 
however, most injuries occur when the bone is fractured or dislocated and inflicts tissue 
damage to the spinal cord.  In addition to altering the biomechanics of injury, performing 
a laminectomy may decrease the intrathecal pressure caused by SCI and thus alter the 
post-injury response. 
Another limitation to this model is that animals must be anesthetized in order to 
perform surgery.  Anesthetic agents cause a loss of consciousness by altering neuronal 
firing patterns.  Although anesthetics are necessary for the surgical procedure, their use 
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may change the effects of injury.  In fact, studies have shown that experimental outcomes 
are dependent upon the type of anesthetic used in the surgical procedure (O'Connor et al. 
2003; Salzman et al. 1990; Statler et al. 2006).  Nembutal was used as the anesthetic of 
choice in our studies due to technical considerations (e.g., long period of anesthesia and 
decreased bleeding during surgery).  Nembutal suppresses the central nervous system by 
potentiating the effects of the inhibitory neurotransmitter GABA and also blocking 
excitatory AMPA receptors.  These receptors are known to play a role in traumatic CNS 
injury (Demediuk et al. 1989b; Diaz-Ruiz et al. 2007; Goda et al. 2002; Goforth et al. 
1999; Gwak et al. 2007).  Therefore, altering receptor activity with an anesthetic may 
have an effect on the injury response.  In addition to these direct effects on the nervous 
system, Nembutal causes systemic effects such as a reduction in blood pressure and 
suppression of the respiratory system, which may alter the systemic response to trauma.  
Although the effects of Nembutal are pointed out here because of its relevance to these 
studies, all anesthetics alter the central nervous system and the overall physiology in 
some way that is likely to affect the results of SCI. However, anesthetics must be used in 
animal research due to ethical and technical considerations and are therefore a necessary 
limitation in the model. 
Although the contusion model is not a perfect replica of human SCI, it is 
nonetheless a powerful tool in SCI research.  Animal models provide a platform for 
obtaining valuable information about injury mechanisms and potential treatment 
strategies.  The ability to induce SCI at a defined anatomical location and with consistent 
mechanical parameters provides a well-controlled system for studying SCI.  Pre-clinical 
testing in animal models such as the one described here can provide evidence that 
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supports new therapies, ultimately aiding in the development and implementation of 
clinically relevant treatments. 
Conclusions 
 Rat spinal cord contusion provides a clinically-relevant model for studying SCI.  
Here we conducted an experiment to validate the use of this model in our laboratory, and 
results demonstrated that we were able to perform surgeries and behavioral testing in a 
manner that produced results similar to previous work.  Contusion SCI caused sustained 
functional impairments in open-field locomotion as well as stepping accuracy on the grid 
walk, although hypersensitivity to a touch stimulus was not observed.  Overall, this study 
provides a foundation for experimental SCI research in our laboratory by optimizing 
methods for performing surgical procedures and behavioral testing so that SCI-induced 
functional deficits can be reliably measured. 
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Figure A.1.  Comparison of BBB scores in naïve, sham, and injured animals.  
Locomotor patterns were observed and scored according to the Basso Beattie Bresnahan 
(BBB) criteria in naïve (n=4), sham (n=6), and injured (n=8) animals up to 57 days post-
surgery.  A sustained behavioral deficit was observed in injured rats compared to sham 
and naïve controls.  There was no difference between sham and naïve animals, indicating 
that surgical procedures were not detrimental to locomotor function (*p<0.001, mean ± 
standard deviation). 
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Figure A.2.  Comparison of grid walk accuracy in naïve, sham, and injured animals.  
Grid walk testing revealed that injured rats (n=8) had significantly more footfalls 
compared to shams (n=6) and naives (n=4) at least up to 57 days post-surgery.  Shams 
and naives were statistically the same, demonstrating that the surgical procedure did not 
impair performance on the grid walk task (*p<0.005, mean ± standard deviation).  
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Figure A.3.  Comparison of von Frey sensitivity in naïve, sham, and injured 
animals.  Von Frey testing was conducted in order to determine the threshold for 
hindlimb withdrawal when a known force was applied to the plantar surface of the paw.  
No significant differences were found between naïve, sham, and injured rats (p>0.05). 
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APPENDIX B 
AUTOMATED GAIT ANALYSIS SYSTEM FOR QUANTITATIVE 
ASSESSMENT OF LOCOMOTION FOLLOWING SPINAL CORD 
INJURY 
 
 
Introduction 
 Assessment of functional outcome is an invaluable aspect of spinal cord injury 
(SCI) animal research.  The animal model provides a unique system in which treatments 
and experimental conditions can be assessed in terms of neurological function.  
Therefore, animal studies with a behavioral component are a powerful and clinically-
relevant experimental test bed for evaluating potential SCI treatments.  Although the 
importance of behavioral assessment is well-understood, there is room to improve upon 
the reliability and sensitivity of the testing methods. 
 Assessment of spontaneous locomotion in the open field is far and away the most 
common form of behavioral testing in SCI research (for review see ((Basso 2004; 
Goldberger et al. 1990; Metz et al. 2000; Muir and Webb 2000)).  Typically, rat hindlimb 
function is assessed in the open field using the Basso Beattie Bresnahan (BBB) scale 
(Basso et al. 1995).  In this test, several qualitative outcomes are combined to form a 
single score that is related to hindlimb locomotion patterns.  Although quick and simple 
to perform, there are several limitations involved with this testing method.  The 
categories in the BBB are defined rather subjectively and require great attention to detail 
during the assessment.  As a result, comparisons between laboratories are not easily made 
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(although it is less problematic if individuals are properly trained (Basso et al. 1996b)).  
In addition, the BBB lacks sensitivity at certain points along the scale (scores between 2 
and 4 and scores above 14), which decreases the statistical power and thus the ability to 
detect a treatment effect (Ferguson et al. 2004; Lankhorst et al. 1999; Popovich et al. 
1999).  Furthermore, scores are assigned based on broad categories (i.e., greater or less 
than 50%) and therefore are not sensitive to smaller changes. 
The CatWalk™ system (Noldus, Leesburg, VA) is a commercially available 
testing apparatus that may address some of the limitations of BBB testing.  The goal is to 
provide a quantitative and objective method for gait analysis for enhancing the sensitivity 
and accuracy of behavioral testing in neuroscience research (Hamers et al. 2006; Hamers 
et al. 2001).  The CatWalk is comprised of a lighted glass walkway, a camera located 
beneath the walkway, and a software analysis system.  When the animal crosses the 
walkway, light reflects down onto the camera and the intensity is recorded.  Using the 
data acquired on video, the software then converts light intensity into gait parameters 
such as stepping pattern, regularity of stepping, stride length, stance duration, timing of 
steps, and base of support (parameters that are not quantitatively measured in the BBB).  
The user can then assess gait characteristics according to what is relevant for that 
particular experimental model. 
In the study presented here, we utilized the CatWalk system for assessment of 
hindlimb function following contusion SCI at T10 vertebral level.  This has been 
performed in other studies of SCI (Deumens et al. 2006; Joosten et al. 2004; Kloos et al. 
2005; Koopmans et al. 2006; Van Meeteren et al. 2003), but has not been established in 
our laboratory.  This study established protocols and baseline parameters for CatWalk 
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testing in our model and demonstrated that SCI-induced deficits can be measured using 
this system in our laboratory.  Future work may utilize this testing method for examining 
the effects of various interventions after SCI. 
Materials and Methods 
Surgical procedures 
 All procedures involving animals were approved by the Georgia Tech Institute of 
Animal Care and Use Committee (protocol A05003).  Six adult male Sprague-Dawley 
rats (250-276g upon arrival) were subjected to moderate SCI at T10 vertebral level, as 
described elsewhere in this dissertation (the most detailed description can be found in 
Appendix A).  Briefly, rats were anesthetized with Nembutal (50 mg/kg) and 
supplemented with isoflurane as necessary.  Asceptic techniques were used.  
Laminectomy was performed at T10 vertebral level, and then the Infinite Horizons spinal 
cord impactor was used to deliver a force of 150 kdyn to the exposed spinal cord.  The 
surgical site was closed with suture in the muscle and staples in the skin.  Post-
operational care ensured that animals remained hydrated and were able to eliminate 
bodily waste. 
 Upon completion of the testing period, animals were euthanized via heavy 
anesthesia with Nembutal followed by transcardial perfusion with phosphate buffered 
saline (PBS) followed by 4% paraformaldehyde.  Three animals were perfused at five 
weeks post-SCI, and the three remaining animals were perfused at eight weeks, in order 
to provide tissue for future histological pilot studies at a variety of time points. 
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CatWalk testing 
Animals were trained to cross the CatWalk prior to baseline testing.  During the 
training period (approximately 6 weeks), a protocol for motivating the animals to cross 
the runway with a consistent velocity was established.  Testing was conducted at night 
during the animal’s wake cycle.  The home cage was placed at the end of the runway with 
a box over the top to darken the cage compared to the lit runway, and animals were 
allowed to enter the home cage at the end of each of the three trials.  Cages were changed 
no less than four days prior to testing in order to intensify the odor.  Placing a gate 
(provided with the CatWalk system) at the beginning of the runway then removing it just 
prior to the trial also improved motivation.  Testing was conducted in the dark to enhance 
the contrast when a paw was placed on the walkway.  All animals underwent baseline 
testing the day before SCI surgery was performed and once per week thereafter.  Three 
sequential trials were captured and analyzed for each animal at each time point. 
After trials were acquired on video, researchers utilized CatWalk software 
(version 7.1) to label limb placement on the runway as right forelimb, right hindlimb, left 
forelimb, or left hindlimb.  An example of the software application can be seen in Figure 
B.1.  The CatWalk system then calculated quantitative values for various gait parameters.  
Data were analyzed using one-way repeated measures ANOVA followed by Dunnett’s 
pairwise test to compare each post-SCI value to baseline (α = 0.05).   
Results and Discussion 
 Although the CatWalk system is capable of generating a very large amount of 
data, only a subset is presented here.  These data were chosen for display because they 
were selected as those that are potentially the most useful for future studies (as 
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determined by a large and sustained injury deficit accompanied by a relatively small 
standard deviation).  A description of the selected parameters can be seen in Table B.1. 
Many of the key parameters demonstrating a behavioral deficit after moderate 
contusion SCI are related to forelimb-hindlimb coordination (specifically shown in 
Figure B.2 as regularity index and phase dispersion mismatch).  As defined by Basso et 
al., a coordinated pass is one in which “for every forelimb step a hindlimb step is taken 
and the hindlimbs alternate”.  Objective evaluation of coordination is a valuable tool 
offered by the CatWalk system, since it is difficult to assess even when the observers are 
experienced.  In addition, achieving coordination is an important and biologically 
significant milestone in post-SCI recovery, since we and others have noted that BBB 
scores after moderate SCI contusion plateau at 13 (Basso et al. 1995; Ferguson et al. 
2004; Scheff et al. 2003).  A score above 13 indicates consistent forelimb-hindlimb 
coordination with deficits in toe clearance, paw rotation, trunk stability, and/or elevation 
of the tail.  A rat must obtain consistent coordination in order to obtain a score above 13; 
therefore, the BBB will not detect an effect if a treatment alters aspects of fine motor 
control but has no effect on coordination.  Several post-hoc transformations that diminish 
have been developed in order to minimize this limitation in the BBB (Ferguson et al. 
2004; Lankhorst et al. 1999; Popovich et al. 1999).  Thus, objective analysis of forelimb-
hindlimb coordination can improve the sensitivity and reliability of open field testing 
(Koopmans et al. 2005). 
Here we observed an SCI-induced decrease in the regularity index, a quantitative 
and objective measure of forelimb-hindlimb coordination.  The regularity index is 
defined as the percent of normal step patterns out of the total number of step sequences.  
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In this study, we observed statistically significant SCI-induced deficits in the regularity 
index at the first week post-injury, but these deficits were not sustained thereafter (Figure 
B.2).  Others have observed longer-term deficits in the regularity index after moderate 
contusion SCI (Hamers et al. 2001; Koopmans et al. 2005; Van Meeteren et al. 2003).  
Diagonal phase dispersion mismatch was also statistically different in injured animals 
one week post-SCI but not at later time points (Figure B.2).  Phase dispersion mismatch 
would be sufficient to decrease the regularity index, and these parameters changed on the 
same time scale; therefore, they are likely to be related. 
In addition to impairments in forelimb-hindlimb coordination, the step sequence 
changed over time after SCI (Figure B.3).  Step sequence patterns and their alterations 
following SCI were first noted by Cheng et al. (1997).  It is important to note that 
variations in the step sequence would not be detected in the regularity index outcome, 
since these are considered normal stepping patterns.  Throughout this study, sequence Ab 
was most commonly used by rats to cross the walkway.  The baseline percentage of Ab 
sequence was a mean value of 88%.  This value dropped to 67% at week one, then 
increased to approximately pre-injury levels and above in subsequent weeks (85%, 98%, 
and 90% at weeks two, three, and four respectively).  In addition, SCI caused animals to 
increase the number of rotate stepping patterns (Ra and Rb) in the first and second week 
post-injury (Figure B.3).  These results show that moderate T10 contusion SCI alters the 
step sequence used by rats.  Others have noted similar alterations in step sequence 
patterns after contusion SCI (Hamers et al. 2001), although a different study showed 
dissimilar baseline and post-SCI step sequence patterns (Koopmans et al. 2005).  Reasons 
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for the discrepancy may include the strain of rat or the pace with which animals crossed 
the platform. 
 The most robust and sustained deficit we observed in this study was in the 
hindlimb base of support.  Hindlimb base of support was statistically greater than 
baseline values at every time point we assessed in this study.  This measure is not 
assessed in the BBB and would therefore provide an additional outcome measure for 
assessment of locomotion when used in combination with the BBB.  Others have shown a 
similar sustained increase in the base of support after contusion SCI, using either the 
CatWalk or footprint analysis as the detection method (Hamers et al. 2001; McEwen and 
Springer 2006; Stokes and Reier 1992). 
In general, the CatWalk is a powerful tool for assessment of functional recovery 
following SCI under various experimental conditions.  However, some important 
technical limitations should be noted.  Although CatWalk is partially automated, it should 
not be misconstrued to be a “high-throughput” testing tool.  Training and motivating 
animals to consistently cross the runway can be extremely time-consuming, and 
inadequate pre-injury training can lead to erroneous results and interpretation.  
Furthermore, labeling of hindlimbs in the CatWalk software is also a large time 
commitment.  All in all, the CatWalk easily requires twice as much time as the BBB or 
grid walk test.  However, this time commitment is balanced by the enormous potential 
offered by quantitative, objective, and accurate data acquisition. 
In the study presented here, we detected SCI-induced deficits with the CatWalk 
system.  Impairments observed were less severe compared to previous publications using 
moderate contusion SCI, although relatively few studies have been conducted using this 
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system to date (Hamers et al. 2001; Koopmans et al. 2005).  There are many potential 
explanations for this outcome, but it is most likely that the SCI device administered an 
impact of less than 150 kdyn (the intended force).  Observations from previous 
behavioral studies (Appendix A, Chapter 5, and other studies not shown) demonstrate a 
less severe injury deficit with each study compared to the previous.  As an example, one 
can compare BBB scores in Appendix A (which was performed first) with those in 
Chapter 4.  The subsequent study showed higher BBB scores, suggesting that the device 
delivered a less severe injury.  The study presented here was performed after the one 
described in Chapter 4 and thus the animals may have been injured with an even lower 
impact force.  Calibration of the device is recommended before any future studies are 
performed. 
 Another potential limitation to the study is the possibility that hindlimb 
locomotion may have changed over time in a way that was not directly related to the 
injury.  During baseline testing, animals did not freely cross the CatWalk and much of the 
recorded video had to be discarded due to pauses in locomotion and hesitance to begin 
the pass at the beginning of the trial.  However, videos from later time points 
demonstrated that the animals quickly and easily crossed the glass walkway with no 
pause at the beginning.  The speed of crossing the walkway can have a large effect on 
gait parameters, which is apparent during BBB testing (personal observation).  Therefore, 
the speed with which the animals cross the walkway is likely to be a large determinant of 
parameters computed by the CatWalk.  A more complete study should include a sham 
group to control for any training effects.  However, we did not include that group in this 
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study out of ethical considerations since this study was intended to be a pilot study for 
optimizing methods and establishing pre- and post-injury baseline values. 
 Given the advantages and limitations provided by the CatWalk system, we 
recommend using this test in conjunction with other behavioral outcome measures.  It is 
generally good practice to evaluate different types of functional recovery, typically 
comprised of testing normal locomotion (e.g., BBB and CatWalk) in addition to a skilled 
sensorimotor task (e.g., grid walk and beam walk).  This is necessary in the event that a 
treatment has a differential effect on these mechanisms of hindlimb function (as we 
observed in Chapter 4) and is consistent with previous recommendations (Basso 2004; 
Muir and Webb 2000).  Utilizing the CatWalk in conjunction with a variety of functional 
measures can lead to a powerful, sensitive study able to detect differences between 
groups when they exist. 
Conclusions 
 The CatWalk system provides a quantitative method for analyzing gait in animal 
models of SCI and other neurological diseases and disorders.  Results obtained from this 
study demonstrate that we are able to utilize this system and obtain deficits in hindlimb 
locomotion following SCI.  Although many parameters can be evaluated with the 
CatWalk, we recommend using this system in combination with other behavioral 
outcome measures such as grid walk.  Assessment of multiple functional outcomes can 
give a better understanding of various aspects of hindlimb function, including gait during 
normal locomotion (as tested in BBB open field and CatWalk) and fine motor control 
(tested with grid and beam walk).  Utilization of various tests may yield different 
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outcomes and paint a more complete picture of treatment effects, as some may be more 
sensitive than others depending on the mechanisms involved. 
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Table B.1.  Description of gait parameters used to assess hindlimb function post-SCI 
with the CatWalk system. 
 
 
 
 
  
Parameter Description 
Regularity Index 
Number of normal step sequence patterns relative to the total 
number of steps.  This value corresponds to “coordination” in the 
BBB scale. 
Hindlimb Base of 
Support Average distance (width) between the hindlimbs. 
Diagonal Phase 
Dispersion 
Mismatch 
The number of peculiarities that occurs between the right forelimb 
(anchor) relative left hindlimb (target) or left forelimb (anchor) 
relative to right hindlimb (target).  A peculiarity is defined as an 
error condition comprised of either placement of the anchor but no 
target placement or placement of the anchor with multiple target 
placements.  In this case, mismatches from the two anchor-target 
combinations were averaged for each animal to form a single score. 
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Figure B.1. Example of CatWalk analysis software screen.  The video of a rat crossing  
the walkway is captured by the CatWalk system and can be displayed using the software.  
Limbs are labeled manually within the software, and then the intensity measurements are 
converted into quantitative data sets related to gait. 
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Figure B.2.  SCI-induced deficits in regularity index and diagonal phase dispersions.  
Moderate SCI caused a decrease in the percentage of normal stepping patterns (regularity 
index) as well as an increase in the number of erroneous steps relative to the diagonal 
limb (phase dispersion mismatch).  These results show that, in our laboratory, CatWalk is 
able to detect impairments in forelimb-hindlimb coordination after rat contusion SCI.  
Impairments were observed one week post-SCI but animals recovered by the second 
week (mean ± standard deviation, n=6, *p<0.05 compared to baseline, B denotes baseline 
score).  
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Figure B.4.  Hindlimb base of support increases after SCI.  Moderate contusion SCI 
increased the width of the hindlimbs.  Deficits were sustained throughout the 4 week 
testing period (mean ± standard deviation, n=6, *p<0.05 compared to baseline, B denotes 
baseline score). 
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